COQ4-Related Neonatal Encephalomyopathy

Mendelian MONDO:0014562 Pathograph 11 Show in embeddings browser Mendelian Disorder Mitochondrial Disorder Inborn Error of Metabolism

Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome (primary coenzyme Q10 deficiency-7, COQ10D7; OMIM 616276) is the severe neonatal-onset form of primary coenzyme Q10 (CoQ10) deficiency caused by biallelic pathogenic variants in COQ4. COQ4 has no known catalytic activity; it is thought to act as a structural organizer that stabilizes the multiheteromeric CoQ biosynthetic complex, so its loss collapses endogenous CoQ10 synthesis rather than blocking one defined enzymatic step. Because CoQ10 is the mobile electron carrier shuttling electrons from complexes I and II to complex III, CoQ10 depletion produces combined deficiency of the CoQ10-dependent segments of the respiratory chain (measured as reduced coupled complex I+III and II+III activities) and failure of oxidative ATP synthesis in the highest-energy-demand tissues - brain, heart, and skeletal muscle. Newborns present on the first day of life with profound hypotonia, encephalopathy with EEG abnormalities and neonatal seizures, hypertrophic cardiomyopathy, respiratory distress or respiratory insufficiency, and rapidly progressive lactic acidosis; antenatal cerebellar hypoplasia and neonatal cerebellar atrophy are characteristic neuroimaging features. Mortality in the neonatal-onset form is very high, and unlike some other primary CoQ10 deficiencies (notably the renal forms), the neonatal COQ4 phenotype responds poorly to high-dose oral CoQ10 supplementation. An exon-dependent genotype-phenotype gradient has been proposed, with variants in exons 5-7 associated with early onset, unresponsiveness to CoQ10 and early death. Founder alleles are recognised in the Ashkenazi Jewish population and in East Asian populations (c.370G>A, p.Gly124Ser).

Ask OpenScientist

Ask a research question about COQ4-Related Neonatal Encephalomyopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
2
Histopath.
23
Phenotypes
3
Gaps
11
Pathograph
4
Genes
3
Medical Actions
1
References
1
Deep Research
🏷

Classifications

Mechanistic Nosology
mitochondrial disease
👪

Inheritance

1
Autosomal Recessive HP:0000007
COQ10D7 is inherited in an autosomal recessive pattern; affected individuals carry homozygous or compound heterozygous COQ4 variants and heterozygous parents are unaffected. Heterozygous carriers of COQ4 nonsense alleles are healthy, arguing against haploinsufficiency as the disease mechanism.
Autosomal recessive inheritance
Show evidence (4 references)
PMID:26185144 SUPPORT Human Clinical
"Mutations in COQ4 cause an autosomal recessive lethal neonatal mitochondrial encephalomyopathy associated with a founder mutation in the Ashkenazi Jewish population."
States the autosomal recessive mode of inheritance for the neonatal COQ4 phenotype.
PMID:25658047 SUPPORT Human Clinical
"All these individuals carried homozygous or compound-heterozygous mutations, clearly indicating that the resulting disease is an autosomal-recessive trait."
Biallelic (homozygous or compound heterozygous) genotypes in all affected subjects establish recessive inheritance.
PMID:25658047 SUPPORT Human Clinical
"Given that the heterozygous parents carrying the nonsense mutations are alive and well, it is unlikely that COQ4 haploinsufficiency is pathogenic"
Healthy heterozygous parents argue that a single loss-of-function allele is insufficient to cause disease, supporting a strictly recessive model.
+ 1 more reference
?

Discussions and Knowledge Gaps

3
Why does exogenous CoQ10 supplementation fail to rescue the neonatal COQ4 phenotype when it can reverse renal disease in other primary CoQ10 deficiencies?
KNOWLEDGE GAP coq4_neonatal_coq10_nonresponse
Attached to
pathophysiology#Coenzyme Q10 Biosynthetic Failure
Oral CoQ10 is the only disease-directed therapy available, yet the neonatal COQ4 form responds poorly and children have died in early childhood despite high-dose CoQ10 from birth. Candidate explanations include inadequate tissue and mitochondrial delivery of the highly lipophilic molecule, irreversible antenatal injury already established at birth, and CoQ10-independent consequences of losing the COQ4 scaffold. Distinguishing these determines whether better-delivered analogues could help or whether the therapeutic window closes before birth.
Proposed experiments
Mitochondrial CoQ10 repletion with alternative formulations
coq4_mito_delivery_rescue
Measure mitochondrial CoQ10 repletion and respiratory-chain rescue in COQ4-patient fibroblasts and cardiomyocytes treated with conventional CoQ10 versus mitochondria-targeted or solubilised formulations.
Prenatal treatment window in a COQ4 model
coq4_prenatal_treatment_window
Determine in a COQ4 model whether prenatal initiation of CoQ10 or a bypass analogue prevents the cerebellar hypoplasia that is already present at birth in human patients.
Show evidence (1 reference)
PMID:34656997 SUPPORT Human Clinical
"Due to the insufficient clinical response to oral CoQ10 supplementation, alternative treatment strategies are warranted."
The authors of the largest COQ4 cohort explicitly frame the treatment failure as an open problem.
What determines whether a given COQ4 genotype produces a heart-dominant, a brain-dominant, or a milder later-onset phenotype?
KNOWLEDGE GAP coq4_tissue_selectivity
Attached to
pathophysiology#Bioenergetic Failure of High-Energy-Demand Tissues
The same biosynthetic lesion yields strikingly different organ involvement and biochemical severity between patients, and respiratory-chain enzymology ranges from multiple defects to none at all. The proposed exon 1-4 versus exon 5-7 gradient is an observational rule that does not explain tissue selectivity, so the modifiers remain unknown.
Show evidence (1 reference)
PMID:25658047 SUPPORT Human Clinical
"This biochemical diversity could be due to differences in individual adaptive responses to reduced CoQ10 availability or could reflect the striking tissue specificity observed in the clinical presentations, but at the moment, a mechanistic explanation for these observations is lacking."
The authors state explicitly that a mechanistic explanation for the tissue selectivity is lacking.
Is the antenatal cerebellar hypoplasia of COQ4 deficiency a developmental patterning failure, or simply prenatal bioenergetic degeneration of an already-formed cerebellum?
KNOWLEDGE GAP coq4_antenatal_developmental_lesion
Attached to
pathophysiology#Bioenergetic Failure of High-Energy-Demand Tissues
The pathophysiology chain modelled in this entry is a postnatal bioenergetic cascade, but cerebellar malformation is detectable at the 20th week of gestation and autopsy shows olivopontocerebellar hypoplasia with microdysgenesis - findings suggesting disturbed development rather than degeneration alone. Whether CoQ10 has a developmental role in cerebellar morphogenesis beyond ATP supply is unresolved, and the answer bounds any therapeutic window, because a patterning failure completed in utero cannot be reversed by postnatal supplementation.
Proposed experiments
Developmental time course of cerebellar CoQ4 loss
coq4_cerebellar_development_timecourse
Track cerebellar progenitor proliferation, migration and foliation in a conditional COQ4-loss model across gestation to distinguish failed morphogenesis from degeneration of formed structures.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"An autopsy of the brain revealed severe olivopontocerebellar and thalamic hypoplasia and scattered cavitations in the white matter"
Hypoplasia and microdysgenesis rather than pure atrophy point to a developmental component that the modelled postnatal bioenergetic chain does not account for.
PMID:26185144 SUPPORT Human Clinical
"Autopsy findings in two patients revealed neuron loss and reactive astrocytosis or cerebellar and brainstem hypoplasia and microdysgenesis."
Microdysgenesis is a developmental lesion, reinforcing the open question.
⚙

Pathophysiology

5
COQ4 Loss of Function and CoQ Synthome Destabilization
Biallelic COQ4 variants reduce or abolish COQ4 protein. COQ4 has no demonstrated catalytic step of its own; the yeast orthologue acts as a structural scaffold stabilizing the multiheteromeric complex that assembles most of the CoQ biosynthetic enzymes, so loss of COQ4 destabilizes the whole biosynthetic machine. Missense, nonsense, frameshift and in-frame deletion alleles have all been reported, and patient fibroblasts show markedly reduced COQ4 protein levels. Note that the molecular-function term below is a curator inference: the cited source states that the precise catalytic function of human COQ4 is unknown and describes it as playing a structural, complex-stabilizing role, for which the adaptor-activity term is the closest available GO proxy.
COQ4 hgnc:19693 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves COQ4 (hgnc:19693). hgnc:19693 is a gene from the HUGO Gene Nomenclature Committee.
protein-macromolecule adaptor activity GO:0030674 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased protein-macromolecule adaptor activity (GO:0030674). GO:0030674 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Coenzyme Q10 Biosynthetic Failure Destabilization of the CoQ biosynthetic complex blocks endogenous CoQ10 production.
Show evidence (3 references)
PMID:25658047 SUPPORT Human Clinical
"The precise function of human COQ4 is not known, but it seems to play a structural role in stabilizing a multiheteromeric complex that contains most of the CoQ10 biosynthetic enzymes."
Establishes the scaffolding role of COQ4 in the CoQ10 biosynthetic complex, the function lost in COQ10D7.
PMID:25658047 SUPPORT In Vitro
"a drastic decrease in the amount of COQ4 was detected by immunoblot analysis in S1, S4, and S5 fibroblasts"
Patient-derived fibroblasts show loss of COQ4 protein, confirming the variants are loss-of-function at the protein level.
PMID:25658047 SUPPORT Model Organism
"oxidative growth, strongly impaired in strains lacking COQ4, was corrected by expression of human wild-type COQ4 cDNA but failed to be corrected by expression of COQ4 cDNAs with any of the mutations identified in affected subjects"
Yeast complementation assays demonstrate that every patient allele causes loss of COQ4 function.
Coenzyme Q10 Biosynthetic Failure
Loss of COQ4 collapses de novo CoQ10 synthesis. Because dietary contribution to cellular CoQ10 is negligible, tissue CoQ10 falls steeply: muscle and fibroblast CoQ10 are severely reduced in affected neonates. The pathway intermediate 6-demethoxyubiquinone accumulates in patient cells, a metabolic signature of COQ4 deficiency that localises the block within the pathway.
ubiquinone biosynthetic process GO:0006744 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ubiquinone biosynthetic process (GO:0006744). GO:0006744 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Impaired CoQ10-Dependent Respiratory Chain Electron Transfer Depletion of the mobile electron carrier interrupts electron flow from complexes I and II to complex III.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"All available specimens from affected subjects showed reduced amounts of CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities."
Directly documents reduced tissue CoQ10 as the biochemical consequence of COQ4 loss.
PMID:34656997 SUPPORT In Vitro
"Experiments revealed significantly decreased COQ4 protein levels, reduced levels of cellular CoQ10 and elevated levels of the metabolic intermediate 6-demethoxyubiquinone."
Patient fibroblast studies link COQ4 protein loss to reduced CoQ10 and accumulation of the upstream intermediate 6-demethoxyubiquinone.
Impaired CoQ10-Dependent Respiratory Chain Electron Transfer
CoQ10 is the lipophilic mobile carrier that shuttles electrons from complex I and complex II (and from other flavoprotein dehydrogenases) to complex III. Its depletion produces a combined, CoQ10-specific respiratory-chain lesion: the coupled complex I+III and complex II+III activities fall while the individual complexes are often preserved, which is the biochemical fingerprint that distinguishes a CoQ10 biosynthesis defect from an assembly defect of a single complex. Maximal respiratory rates are reduced in patient fibroblasts.
electron transport chain GO:0022900 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased electron transport chain (GO:0022900). GO:0022900 is a biological process from the Gene Ontology. ↓ DECREASED oxidative phosphorylation GO:0006119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased oxidative phosphorylation (GO:0006119). GO:0006119 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Bioenergetic Failure of High-Energy-Demand Tissues Loss of oxidative ATP synthesis preferentially injures tissues with the highest energy demand and CoQ10 content.
Show evidence (3 references)
PMID:25658047 SUPPORT Human Clinical
"CoQ10 is an essential component of the electron transport chain (ETC), where it shuttles electrons from complex I or II to complex III."
Establishes the electron-carrier role of CoQ10 whose loss produces the combined respiratory-chain defect.
PMID:28540186 SUPPORT In Vitro
"the combined activities of CoQ10-dependent complexes i.e., rotenone-sensitive NADH cytochrome c reductase (complex I + III) and succinate-cytochrome c reductase (complex II + III) were also found to be significantly reduced, whereas the activities of other complexes were essentially comparable..."
Demonstrates the selective loss of coupled CoQ10-dependent segments with preserved individual complexes, the hallmark of CoQ10 deficiency.
PMID:25658047 SUPPORT In Vitro
"we detected that maximal respiratory rates were lower in S1, S4, and S5 fibroblasts than in control cells"
Respirometry in patient fibroblasts confirms a functional bioenergetic deficit.
Bioenergetic Failure of High-Energy-Demand Tissues
Organs with the highest oxidative workload - in the cited source the heart, kidneys and brain - carry the highest CoQ10 concentrations and fail first. In the neonatal COQ4 phenotype the injury falls on heart, brain and skeletal muscle, with renal function repeatedly reported as spared, distinguishing COQ4 from the renal-predominant COQ2/COQ6/COQ8B forms. The fulminant course of the neonatal form can mask multisystem involvement, so individual infants may appear predominantly cardiac or predominantly neurological. The specific cardiac and neural tissue lesions produced are curated under `histopathology`.
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology. neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
mitochondrial ATP synthesis coupled electron transport GO:0042775 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased mitochondrial ATP synthesis coupled electron transport (GO:0042775). GO:0042775 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Rapidly Progressive Lactic Acidosis and Multiorgan Failure Blocked oxidative metabolism forces anaerobic glycolysis with lactate accumulation and precipitates multiorgan failure.
Show evidence (4 references)
PMID:25658047 SUPPORT Other
"organs with the highest energy requirements, such as the heart, kidneys, and brain, have the highest CoQ10 concentrations"
Explains the tissue selectivity of CoQ10 deficiency towards high-energy-demand organs; this is a review-level background assertion in the discussion rather than a patient observation.
PMID:25658047 SUPPORT Human Clinical
"No evidence of hepatic or renal impairment was observed."
Supports renal and hepatic sparing in the index neonate, the feature that separates COQ4 disease from the renal-predominant CoQ10 deficiencies.
PMID:28540186 SUPPORT Human Clinical
"There was no evidence of renal dysfunction, transaminitis or liver synthetic dysfunction."
Independently confirms renal and hepatic sparing in a COQ4-deficient infant.
+ 1 more reference
Rapidly Progressive Lactic Acidosis and Multiorgan Failure
With oxidative phosphorylation blocked, pyruvate is shunted to lactate and blood lactate rises steeply in the first hours to days of life. Severe lactic acidosis in combination with cardiac and respiratory failure determines the fatal outcome of the classic neonatal presentation.
lactate metabolic process GO:0006089 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased lactate metabolic process (GO:0006089). GO:0006089 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"Rapidly progressive, severe lactic acidosis was a common feature in all four affected newborn subjects and is likely to have determined their fatal outcome."
Directly links the lactic acidosis of the neonatal COQ4 phenotype to mortality.
PMID:39398416 SUPPORT Human Clinical
"Hyperlactatemia was one of the most common manifestations, accounting for 75% of cases (18/24)."
Quantifies hyperlactatemia across the published neonatal-onset COQ4 cohort.
✶

Histopathology

2
Biventricular Cardiac Hypertrophy with Abnormal Cardiomyocyte Mitochondria
Autopsy of an affected infant showed marked biventricular cardiac hypertrophy; electron microscopy of cardiomyocyte mitochondria showed swollen organelles with loss of cristae and unusual semi-circular cristae arrangements, while kidney and liver mitochondria were unremarkable - consistent with tissue-selective bioenergetic injury.
Show evidence (2 references)
PMID:28540186 SUPPORT Human Clinical
"At autopsy, there was marked bi-ventricular cardiac hypertrophy. EM studies of cardiomyocytes mitochondria showed swollen mitochondria with loss of cristae and some mitochondria with semi-circular arrangements of cristae"
Describes the cardiac ultrastructural pathology of COQ4 deficiency.
PMID:28540186 SUPPORT Human Clinical
"Light microscopy and EM studies of mitochondria in the kidney and liver were unremarkable."
Confirms the tissue selectivity of the ultrastructural injury (heart affected, kidney and liver spared).
Neuronal Loss with Reactive Astrocytosis and Cerebellar-Brainstem Hypoplasia
Neuropathology in the defining cohort showed neuron loss with reactive astrocytosis in one patient and cerebellar and brainstem hypoplasia with microdysgenesis in another, matching the neuroimaging finding of cerebellar atrophy.
Show evidence (1 reference)
PMID:26185144 SUPPORT Human Clinical
"Autopsy findings in two patients revealed neuron loss and reactive astrocytosis or cerebellar and brainstem hypoplasia and microdysgenesis."
Documents the neuropathological substrate of the encephalomyopathy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for COQ4-Related Neonatal Encephalomyopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

23
Cardiovascular 3
Cardiomyopathy VERY_FREQUENT HP:0001638 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cardiomyopathy (HP:0001638). HP:0001638 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Cardiomyopathy in 5/6 patients (83%) supports the VERY_FREQUENT band at the generic cardiomyopathy level.
Hypertrophic Cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:25658047 SUPPORT Human Clinical
"The pregnancy was complicated by severe intrauterine growth delay and ultrasound-documented hypertrophic cardiomyopathy."
Specifies the hypertrophic subtype and its antenatal detectability.
PMID:28540186 SUPPORT Human Clinical
"Here we report novel mutations in the COQ4 gene, which were identified in an infant with profound mitochondrial disease presenting with perinatal seizures, hypertrophic cardiomyopathy and severe muscle CoQ10 deficiency."
Independent report confirming hypertrophic cardiomyopathy with severe muscle CoQ10 deficiency.
PMID:28540186 SUPPORT Human Clinical
"Biventricular hypertrophy was observed by echocardiogram."
Echocardiographic confirmation of biventricular hypertrophy in an affected infant.
Bradycardia HP:0001662 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bradycardia (HP:0001662). HP:0001662 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25658047 SUPPORT Human Clinical
"Two unrelated individuals presented with severe hypotonia, bradycardia, respiratory insufficiency, and heart failure"
Bradycardia is documented as a neonatal presenting sign.
Digestive 1
Feeding Difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38353291 SUPPORT Human Clinical
"A 1-year-old male was admitted to our clinic with complaints of hypotonia, seizures, and feeding difficulties."
Feeding difficulties are a presenting complaint in a molecularly confirmed COQ10D7 patient.
PMID:28540186 SUPPORT Human Clinical
"Additional problems included gastroesophageal reflux requiring fundoplication"
Documents severe reflux requiring surgical management in COQ4 deficiency.
Ear 1
Hearing Impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28540186 SUPPORT Human Clinical
"Additional problems included gastroesophageal reflux requiring fundoplication, delayed visual maturation without structural abnormality of the eyes, bilateral hearing loss, profound hypotonia and absence of development."
Bilateral hearing loss is documented in a COQ4-deficient infant.
Eye 2
Nystagmus HP:0000639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nystagmus (HP:0000639). HP:0000639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38353291 SUPPORT Human Clinical
"A physical examination revealed microcephaly, a high palate, poor feeding, weak crying, hypotonia, bilateral horizontal nystagmus, and inability to maintain eye contact."
Documents bilateral horizontal nystagmus on examination in a molecularly confirmed COQ10D7 patient.
Visual Impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28540186 SUPPORT Human Clinical
"delayed visual maturation without structural abnormality of the eyes"
Documents visual impairment of central origin in a COQ4-deficient infant.
Head and Neck 2
Microcephaly HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28540186 SUPPORT Human Clinical
"Subsequent MRI at 10 weeks showed microcephaly with volume loss and increasing prominence of lactate peaks."
Serial neuroimaging documents acquired microcephaly with cerebral volume loss.
PMID:38353291 SUPPORT Human Clinical
"A physical examination revealed microcephaly, a high palate, poor feeding, weak crying, hypotonia, bilateral horizontal nystagmus, and inability to maintain eye contact."
Microcephaly on clinical examination in a molecularly confirmed COQ10D7 patient.
Dysmorphic Features Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:38353291 SUPPORT Human Clinical
"A physical examination revealed hypotonia, a dolichocephaly, periorbital edema, and long eyelashes."
Enumerates the dysmorphic findings in a molecularly confirmed COQ10D7 patient.
PMID:38353291 SUPPORT Human Clinical
"Primary Coenzyme Q10 Deficiency-7 should be considered in the differential diagnosis of infants presenting with neurological and dysmorphic manifestations."
The authors' conclusion establishes dysmorphism as a recognised part of the COQ10D7 presentation.
Metabolism 1
Lactic Acidosis FREQUENT HP:0003128 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lactic acidosis (HP:0003128). HP:0003128 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Lactic acidosis in 4/6 patients (67%) maps to the FREQUENT (30-79%) band.
PMID:25658047 SUPPORT Human Clinical
"Rapidly progressive, severe lactic acidosis was a common feature in all four affected newborn subjects and is likely to have determined their fatal outcome."
Confirms severe, rapidly progressive lactic acidosis in the neonatal subgroup.
Musculoskeletal 2
Neonatal Hypotonia VERY_FREQUENT HP:0001319 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal hypotonia (HP:0001319). HP:0001319 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Hypotonia was present in 6/6 neonatal COQ4 patients, supporting a VERY_FREQUENT (80-100%) frequency band.
PMID:25658047 SUPPORT Human Clinical
"Two unrelated individuals presented with severe hypotonia, bradycardia, respiratory insufficiency, and heart failure"
Independent cohort confirming severe neonatal hypotonia as a presenting feature.
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37948995 SUPPORT Human Clinical
"The typical manifestations include early pharmacoresistant seizure, severe cognition and/or developmental delay, dystonia, ataxia, and spasticity."
Names spasticity among the typical manifestations of COQ4-related CoQ10 deficiency; PARTIAL because the review describes the full COQ4 spectrum rather than the neonatal-onset form specifically.
Nervous System 6
Encephalopathy FREQUENT HP:0001298 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Encephalopathy (HP:0001298). HP:0001298 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Encephalopathy with EEG abnormalities was found in 4/4 patients assessed by EEG. Because the denominator of the whole cohort is 6, the conservative intention-to-ascertain estimate is 4/6 (67%), which maps to FREQUENT rather than VERY_FREQUENT.
Cerebellar Atrophy VERY_FREQUENT HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272). HP:0001272 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Cerebellar atrophy in 4/5 imaged patients (80%) supports the VERY_FREQUENT band.
Antenatal Cerebellar Hypoplasia HP:0001321 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar hypoplasia (HP:0001321), qualified as antenatal onset. HP:0001321 is a phenotype from the Human Phenotype Ontology.
Onset: ANTENATAL
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"Performed at the 20th week of gestation, prenatal organ screening of S3 revealed a suspected malformation of the cerebellum."
Documents antenatal detection of the cerebellar malformation at 20 weeks gestation.
PMID:25658047 SUPPORT Human Clinical
"two sisters showed antenatal cerebellar hypoplasia, neonatal respiratory-distress syndrome, and epileptic encephalopathy"
Confirms antenatal cerebellar hypoplasia in both affected sisters.
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28540186 SUPPORT Human Clinical
"profound hypotonia and absence of development"
Documents complete absence of developmental progress in a COQ4-deficient infant.
PMID:37948995 SUPPORT Human Clinical
"The typical manifestations include early pharmacoresistant seizure, severe cognition and/or developmental delay, dystonia, ataxia, and spasticity."
Lists severe cognitive and developmental delay among the typical manifestations of COQ4-related CoQ10 deficiency.
Dystonia HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332). HP:0001332 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37948995 SUPPORT Human Clinical
"The typical manifestations include early pharmacoresistant seizure, severe cognition and/or developmental delay, dystonia, ataxia, and spasticity."
Names dystonia among the typical manifestations of COQ4-related CoQ10 deficiency; PARTIAL because the review describes the full COQ4 spectrum rather than the neonatal-onset form specifically.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37948995 SUPPORT Human Clinical
"The typical manifestations include early pharmacoresistant seizure, severe cognition and/or developmental delay, dystonia, ataxia, and spasticity."
Names ataxia among the typical manifestations of COQ4-related CoQ10 deficiency; PARTIAL because the review describes the full COQ4 spectrum rather than the neonatal-onset form specifically.
Respiratory 2
Neonatal Respiratory Distress HP:0002643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal respiratory distress (HP:0002643). HP:0002643 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"two sisters showed antenatal cerebellar hypoplasia, neonatal respiratory-distress syndrome, and epileptic encephalopathy"
Documents neonatal respiratory distress syndrome in COQ4-mutant neonates.
PMID:38353291 SUPPORT Human Clinical
"Common clinical findings include hypotonia, seizures, respiratory distress, and cardiomyopathy."
A review of published COQ10D7 cases lists respiratory distress among the common findings.
Respiratory Insufficiency HP:0002093 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Respiratory insufficiency (HP:0002093). HP:0002093 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"Two unrelated individuals presented with severe hypotonia, bradycardia, respiratory insufficiency, and heart failure"
Respiratory insufficiency is documented as a presenting neonatal feature.
PMID:25658047 SUPPORT Human Clinical
"she became apnoeic and was intubated as a result of respiratory failure"
Illustrates first-day-of-life respiratory failure requiring ventilation.
Growth 1
Intrauterine Growth Retardation HP:0001511 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intrauterine growth retardation (HP:0001511). HP:0001511 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"The pregnancy was complicated by severe intrauterine growth delay and ultrasound-documented hypertrophic cardiomyopathy."
Documents severe intrauterine growth restriction in an affected pregnancy.
PMID:39398416 SUPPORT Human Clinical
"The incidence of prenatal abnormalities in preterm infants was significantly higher than that in full-term infants (66.7% vs. 16.7%, P = 0.02)."
Supports the antenatal-abnormality burden in preterm affected infants; indirect for growth restriction specifically, hence PARTIAL.
Other 2
Epileptic Encephalopathy HP:0200134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epileptic encephalopathy (HP:0200134). HP:0200134 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"two sisters showed antenatal cerebellar hypoplasia, neonatal respiratory-distress syndrome, and epileptic encephalopathy"
Documents neonatal epileptic encephalopathy in COQ4-mutant sisters.
PMID:34656997 SUPPORT Human Clinical
"type 1: early-onset phenotype with neonatal brain anomalies and epileptic encephalopathy"
The large COQ4 cohort defines the early-onset (neonatal) pattern by brain anomalies plus epileptic encephalopathy.
Neonatal Seizures FREQUENT HP:0032807 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26185144 SUPPORT Human Clinical
"Clinical findings included hypotonia (6/6), encephalopathy with EEG abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5), cardiomyopathy (5/6) and lactic acidosis (4/6)."
Neonatal seizures in 3/6 patients (50%) maps to the FREQUENT (30-79%) band.
PMID:28540186 SUPPORT Human Clinical
"Seizure management was initially acceptable, but the patient eventually became refractory to multi-drug therapy (phenobarbital, topiramate, clobazam)."
Illustrates the pharmacoresistant character of seizures in COQ4 deficiency.
🧬

Genetic Associations

4
COQ4 biallelic pathogenic variants
Gene: COQ4 hgnc:19693 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COQ4 (hgnc:19693). hgnc:19693 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:31396399 SUPPORT Human Clinical
"Primary coenzyme Q10 deficiency-7 (COQ10D7) is a rare mitochondrial disease caused by biallelic mutations in COQ4."
Establishes COQ4 as the causal gene for COQ10D7, the entity curated here.
PMID:38353291 SUPPORT Human Clinical
"Primary Coenzyme Q10 Deficiency-7 (OMIM 616276) results from bi-allelic pathogenic variants in the COQ4 gene."
Independently ties the OMIM 616276 entity - the xref of MONDO:0014562 - to biallelic COQ4 variants, confirming gene identity.
PMID:25658047 SUPPORT Human Clinical
"codes for a ubiquitously expressed 265-amino-acid protein that is peripherally associated with the mitochondrial inner membrane on the matrix side"
Describes the COQ4 gene product and its submitochondrial localisation.
Ashkenazi Jewish founder allele
Gene: COQ4 hgnc:19693 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COQ4 (hgnc:19693). hgnc:19693 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:26185144 SUPPORT Human Clinical
"One mutation was found in a homozygous state in two unrelated Ashkenazi Jewish probands."
Identifies the Ashkenazi Jewish founder allele.
PMID:26185144 SUPPORT Human Clinical
"Mutations in COQ4 cause an autosomal recessive lethal neonatal mitochondrial encephalomyopathy associated with a founder mutation in the Ashkenazi Jewish population."
Explicitly designates the variant as an Ashkenazi Jewish founder mutation.
c.370G>A p.(Gly124Ser) East Asian founder allele
Gene: COQ4 hgnc:19693 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COQ4 (hgnc:19693). hgnc:19693 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (3 references)
PMID:31396399 SUPPORT Human Clinical
"We also identify a founder mutation COQ4 (NM_016035.5): c.370G>A, p.(Gly124Ser) for COQ10D7, suggesting a higher chance of occurrence in the southern Chinese."
Identifies and names the southern Chinese founder allele.
PMID:37948995 SUPPORT Human Clinical
"Among those patients, c.370G > A variant is the most common pathogenic variant detected, especially in Asian population."
Confirms c.370G>A as the predominant COQ4 allele in Asian patients.
PMID:35154243 SUPPORT Human Clinical
"Patients with the East Asian-specific c.370G > A variant displays intermediate disease severity with multi-systemic dysfunction, which is between that of the patients with variants in exons 1-4 and 5-7."
Places the East Asian founder allele at intermediate severity within the exon-dependent gradient.
Exon-dependent genotype-phenotype gradient
Gene: COQ4 hgnc:19693 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COQ4 (hgnc:19693). hgnc:19693 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:35154243 SUPPORT Human Clinical
"Pathogenic COQ4 variants in exons 1-4 are associated with less life-threating presentations, late onset, responsiveness to CoQ10 therapy, and a relatively long lifespan. In contrast, pathogenic COQ4 variants in exons 5-7 are associated with early onset, unresponsiveness to CoQ10 therapy, and..."
States the exon-dependent genotype-phenotype gradient, placing the severe neonatal phenotype with exon 5-7 variants; PARTIAL because this is an observational correlation proposed in a narrative review, not a validated predictor.
PMID:35154243 SUPPORT Human Clinical
"Sex is shown unlikely to be associated with disease severity."
Excludes sex as a severity modifier; PARTIAL because it is a review-level observation rather than a powered analysis.
💊

Medical Actions

3
High-Dose Oral Coenzyme Q10 Supplementation
Action: coenzyme Q10 supplementationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is coenzyme Q10 supplementation, annotated with Nutritional Supplementation (NCIT:C15425). NCIT:C15425 is a clinical intervention from the NCI Thesaurus. Ontology label: Nutritional Supplementation NCIT:C15425
Agent: coenzyme Q10 CHEBI:46245 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses coenzyme Q10 (CHEBI:46245). CHEBI:46245 is a therapeutic agent from Chemical Entities of Biological Interest.
Oral CoQ10 (ubiquinone/ubiquinol) supplementation is the only disease-directed therapy and is the rationale for urgent diagnosis, since cofactor deficiencies are among the very few mitochondrial disorders with a pharmacological treatment. Its benefit in the neonatal COQ4 phenotype is limited: response was insufficient in the largest COQ4 cohort, and in the published neonatal series only nine of twenty-four patients received CoQ10, although all four survivors had done so. In a specialist CoQ10-biosynthesis cohort, oral doses up to 70 mg/kg/day were needed to ameliorate neurologic features and 30 mg/kg/day reversed or prevented renal disease, but three children with neonatal-onset neurologic disease still died in early childhood despite high-dose CoQ10 from birth. Exogenous CoQ10 cannot fully bypass the biosynthetic block in established neonatal CNS disease, and families of infants with neonatal neurologic presentations should be counselled about the poor prognosis.
Mechanism Target:
BYPASSES Coenzyme Q10 Biosynthetic Failure — Exogenous CoQ10 attempts to supply the product that the disrupted biosynthetic complex can no longer make, bypassing the synthetic block rather than repairing it.
Show evidence (8 references)
PMID:34656997 SUPPORT Human Clinical
"Due to the insufficient clinical response to oral CoQ10 supplementation, alternative treatment strategies are warranted."
Documents the limited efficacy of oral CoQ10 in COQ4 deficiency, tempering the treatment claim.
PMID:39398416 SUPPORT Human Clinical
"Only 9 patients received exogenous coenzyme Q10 treatment, and all the 4 surviving patients received coenzyme Q10 supplementation."
All survivors in the neonatal series received CoQ10, but the uncontrolled observation cannot establish efficacy, hence PARTIAL.
PMID:26185144 SUPPORT INDIRECT Human Clinical
"Mutations in genes involved in CoQ(10) biosynthesis cause primary CoQ(10) deficiency syndromes that can be treated with oral supplementation of ubiquinone."
States the therapeutic rationale for oral ubiquinone across primary CoQ10 deficiency as a class; INDIRECT because it is a background statement about the disorder group, not evidence of efficacy in the neonatal COQ4 form.
+ 5 more references
Idebenone
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: idebenone CHEBI:31687 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses idebenone (CHEBI:31687). CHEBI:31687 is a therapeutic agent from Chemical Entities of Biological Interest.
Idebenone, a synthetic short-chain CoQ10 analogue, has been used as an adjunct to control seizures in some patients with CoQ10 biosynthesis disorders when high-dose CoQ10 alone was insufficient. Evidence is limited to a retrospective single-centre cohort of CoQ10 biosynthesis disorders rather than a COQ4-specific study.
Mechanism Target:
BYPASSES Impaired CoQ10-Dependent Respiratory Chain Electron Transfer — Idebenone is a short-chain quinone that can shuttle electrons in the respiratory chain independently of endogenous CoQ10, so it acts on the electron-transfer node rather than on the biosynthetic block itself.
Show evidence (1 reference)
PMID:39601013 SUPPORT Human Clinical
"Additional idebenone was required to control seizures in some cases, and 3 children with neonatal-onset neurologic disease died in early childhood despite receiving high-dose oral CoQ10 from birth."
Documents adjunctive idebenone for seizure control in a CoQ10 biosynthesis-disorder cohort; PARTIAL because the observation is uncontrolled and not COQ4-specific.
Neonatal Intensive Supportive Care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Management of the neonatal presentation is otherwise supportive: mechanical ventilation for respiratory failure, inotropic support for cardiac failure (which was ineffective in the first reported COQ4 neonate, who died four hours after birth), management of lactic acidosis, and anti-epileptic therapy for often-refractory seizures. Given the very high mortality, palliative care and genetic counselling for recurrence risk are integral.
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"Dobutamine infusion via an umbilical venous catheter was ineffective, and the baby died 4 hr after birth."
Illustrates the failure of inotropic support in fulminant neonatal COQ4 cardiac failure.
PMID:28540186 SUPPORT Human Clinical
"He was discharged on palliative measures but was readmitted six days later with profound acidosis and respiratory failure."
Documents the palliative trajectory typical of severe COQ4 disease.
🔬

Biochemical Markers

4
Reduced tissue coenzyme Q10 (DECREASED)
Show evidence (2 references)
PMID:25658047 SUPPORT Human Clinical
"All available specimens from affected subjects showed reduced amounts of CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities."
Reduced tissue CoQ10 is documented across all available patient specimens.
PMID:28540186 SUPPORT Human Clinical
"The levels of CoQ10 in autopsied skeletal muscle (6.9 μg/g tissue; normal range 19.6–46.8) and in skin fibroblasts (19.1 μg/mg protein; normal range 45.4–65.7) were found to be severely reduced."
Provides quantitative muscle and fibroblast CoQ10 values against laboratory reference ranges.
Elevated 6-demethoxyubiquinone (INCREASED)
Show evidence (1 reference)
PMID:34656997 SUPPORT In Vitro
"Experiments revealed significantly decreased COQ4 protein levels, reduced levels of cellular CoQ10 and elevated levels of the metabolic intermediate 6-demethoxyubiquinone."
Documents accumulation of 6-demethoxyubiquinone in COQ4-deficient cells.
Increased circulating lactate concentration (INCREASED)
Show evidence (2 references)
PMID:39398416 SUPPORT Human Clinical
"Hyperlactatemia was one of the most common manifestations, accounting for 75% of cases (18/24)."
Quantifies hyperlactatemia in 18 of 24 published neonatal COQ4 cases.
PMID:25658047 SUPPORT Human Clinical
"her lactic acidosis rapidly worsened (blood lactate = 11.2–18.8 mM; n.v. < 2)"
Gives measured blood lactate values against the laboratory normal value in an affected neonate.
Reduced coupled complex I+III and II+III activities (DECREASED)
Show evidence (2 references)
PMID:28540186 SUPPORT In Vitro
"the combined activities of CoQ10-dependent complexes i.e., rotenone-sensitive NADH cytochrome c reductase (complex I + III) and succinate-cytochrome c reductase (complex II + III) were also found to be significantly reduced, whereas the activities of other complexes were essentially comparable..."
Demonstrates the selective coupled-activity defect diagnostic of CoQ10 deficiency.
PMID:25658047 SUPPORT Human Clinical
"Clinical heterogeneity was accompanied by an equally striking variability of the biochemical findings, which ranged from multiple (S1 and S5) to isolated (S2 and S3) ETC defects in muscle and fibroblasts to hardly any detectable defect at all (S4)."
Documents the variability of respiratory-chain findings, which limits the sensitivity of enzymology as a diagnostic test.
🔬

Diagnosis

2
Whole exome sequencing
Molecular genetic testing, predominantly whole exome sequencing, is the principal route to diagnosis; twenty of twenty-four published neonatal-onset cases were diagnosed this way. Because the neonatal course is fulminant, a rapid genome-wide approach is required for the diagnosis to be actionable, and no pathognomonic blood, muscle or imaging biomarker exists.
Show evidence (3 references)
PMID:39398416 SUPPORT Human Clinical
"Twenty of the 24 cases were diagnosed by whole exome sequencing."
Establishes exome sequencing as the dominant diagnostic modality.
PMID:39601013 SUPPORT Human Clinical
"An early genome-wide diagnostic approach is needed for expeditious diagnosis of CoQ10 biosynthesis disorder because our study demonstrates that there are no pathognomonic blood, muscle, or imaging biomarkers of these diseases."
Justifies genome-wide testing as first-line by the absence of a pathognomonic biomarker.
PMID:28125198 SUPPORT Human Clinical
"Provide an evaluation strategy to identify the genetic cause of primary CoQ10 deficiency in a proband."
GeneReviews treats identifying the genetic cause in a proband as a defined evaluation strategy, which is the diagnostic pathway this entry models; PARTIAL because the abstract states the overview's aim rather than naming exome sequencing as the specific modality.
Tissue coenzyme Q10 quantification and respiratory chain enzymology
Measurement of CoQ10 in skeletal muscle or cultured fibroblasts by reversed-phase HPLC with electrochemical detection confirms the biochemical deficiency, and coupled respiratory-chain assays show the CoQ10-dependent pattern. Mitochondrial functional verification is recommended alongside genetic testing in high-incidence regions.
Show evidence (2 references)
PMID:39398416 SUPPORT Human Clinical
"To improve the diagnostic rate, in addition to genetic testing, mitochondrial functional verification should be prioritized in southern China, where the incidence is relatively high."
Recommends mitochondrial functional testing as a complement to genetic diagnosis.
PMID:35154243 SUPPORT Human Clinical
"biochemical analyses of the characteristic impairments in CoQ10 biosynthesis and mitochondrial respiratory chain activity, as well as the phenotypic rescue of the CoQ10 treatment, are necessary to confirm the pathogenicity of suspicious variants"
Positions biochemical assays as necessary confirmation of variant pathogenicity.
📈

Progression

3
Antenatal
Prenatal manifestations may include cerebellar malformation on second trimester organ screening, intrauterine growth restriction, fetal hypertrophic cardiomyopathy and preterm delivery.
Show evidence (1 reference)
PMID:25658047 SUPPORT Human Clinical
"Performed at the 20th week of gestation, prenatal organ screening of S3 revealed a suspected malformation of the cerebellum."
Antenatal cerebellar malformation can be the earliest detectable sign.
Neonatal presentation
Age: First day of life
Presentation is on the first day of life with hypotonia, encephalopathy, respiratory distress or insufficiency, cardiomyopathy and rising lactate.
Show evidence (1 reference)
PMID:26185144 SUPPORT Human Clinical
"All patients were female, and presented on the first day of life, and died in the neonatal period or early infancy."
Defines first-day-of-life onset for the neonatal COQ4 phenotype.
Neonatal and early infantile death
Most affected neonates die within days to weeks; pooled mean survival across published neonatal-onset cases is about 60 days, and mortality did not differ significantly between Chinese and other reported cohorts.
Show evidence (2 references)
PMID:39398416 SUPPORT Human Clinical
"The survival time for the 24 cases was 60.0 ± 98.0 days (95% confidence interval CI: 0-252.0 days)."
Quantifies survival across 24 published neonatal-onset COQ4 cases.
PMID:39398416 SUPPORT Human Clinical
"There was no statistically significant difference in the mortality between Chinese (9/12, 75%) and other regions (11/12, 91.7%) (P = 0.27)."
Quantifies mortality in both reported geographic groups.
📊

Prevalence

2
Worldwide
Cases In Literature Ultra Rare
The largest published series characterised 44 individuals from 36 families across all COQ4 phenotypes, of which the neonatal-onset form is a subset; a separate review aggregated 24 neonatal-onset cases. No population-based rate has been published, so a qualitative band is used.
Show evidence (1 reference)
PMID:34656997 SUPPORT Human Clinical
"We characterised 44 individuals from 36 families with COQ4 deficiency (16 newly described)."
The largest published COQ4 cohort totals 44 individuals, supporting an ultra-rare classification.
Southern Chinese
Unknown Unknown
A founder allele raises the regional occurrence in southern China; no quantitative population rate has been published.
Show evidence (1 reference)
PMID:31396399 SUPPORT Human Clinical
"We also identify a founder mutation COQ4 (NM_016035.5): c.370G>A, p.(Gly124Ser) for COQ10D7, suggesting a higher chance of occurrence in the southern Chinese."
Supports a regionally elevated occurrence without a quantitative rate.
{ }

Source YAML

click to show 
name: COQ4-Related Neonatal Encephalomyopathy
category: Mendelian
creation_date: "2026-08-01T00:00:00Z"
synonyms:
- neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
- primary coenzyme Q10 deficiency-7
- COQ10D7
- COQ4-related neonatal encephalomyopathy
- COQ4 deficiency, neonatal-onset form
description: >
  Neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
  (primary coenzyme Q10 deficiency-7, COQ10D7; OMIM 616276) is the severe
  neonatal-onset form of primary coenzyme Q10 (CoQ10) deficiency caused by
  biallelic pathogenic variants in COQ4. COQ4 has no known catalytic activity;
  it is thought to act as a structural organizer that stabilizes the
  multiheteromeric CoQ biosynthetic complex, so its loss collapses endogenous
  CoQ10 synthesis rather than blocking one defined enzymatic step. Because
  CoQ10 is the mobile electron carrier shuttling electrons from complexes I and
  II to complex III, CoQ10 depletion produces combined deficiency of the
  CoQ10-dependent segments of the respiratory chain (measured as reduced
  coupled complex I+III and II+III activities) and failure of oxidative ATP
  synthesis in the highest-energy-demand tissues - brain, heart, and skeletal
  muscle. Newborns present on the first day of life with profound hypotonia,
  encephalopathy with EEG abnormalities and neonatal seizures, hypertrophic
  cardiomyopathy, respiratory distress or respiratory insufficiency, and
  rapidly progressive lactic acidosis; antenatal cerebellar hypoplasia and
  neonatal cerebellar atrophy are characteristic neuroimaging features.
  Mortality in the neonatal-onset form is very high, and unlike some other
  primary CoQ10 deficiencies (notably the renal forms), the neonatal COQ4
  phenotype responds poorly to high-dose oral CoQ10 supplementation. An
  exon-dependent genotype-phenotype gradient has been proposed, with variants
  in exons 5-7 associated with early onset, unresponsiveness to CoQ10 and early
  death. Founder alleles are recognised in the Ashkenazi Jewish population and
  in East Asian populations (c.370G>A, p.Gly124Ser).
disease_term:
  preferred_term: neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
  term:
    id: MONDO:0014562
    label: neonatal encephalomyopathy-cardiomyopathy-respiratory distress syndrome
parents:
- Mendelian Disorder
- Mitochondrial Disorder
- Inborn Error of Metabolism
notes: >
  Scope and positioning. This entry is the gene- and onset-specific child of the
  existing umbrella entry Primary_Coenzyme_Q10_Deficiency (MONDO:0018151), which
  carries COQ4 only as a brief subtype stub alongside the other CoQ10
  biosynthesis genes. MONDO:0014562 is_a MONDO:0018151. Consistent with the
  project's umbrella-plus-per-type modelling, the mechanism and evidence
  specific to the neonatal COQ4 phenotype are curated here rather than blended
  into the umbrella graph.
  Scope anchor: the largest COQ4 cohort resolves the disorder into three
  patterns, and this entry is scoped to their type 1 - the early-onset
  phenotype with neonatal brain anomalies and epileptic encephalopathy (see the
  Epileptic Encephalopathy phenotype for the quoted definition). Type 2
  (intermediate, stroke-like lesions) and type 3 (moderate, stable course) sit
  in the broader COQ4 spectrum and belong with the umbrella entry, not here.
  Several survivor-phase features (developmental delay, dystonia, ataxia,
  spasticity, hearing and visual impairment) are curated because affected
  infants who survive the neonatal period develop them, but their supporting
  sources describe the whole COQ4 spectrum, so they carry PARTIAL evidence and
  no frequency band.
  Named Entity Confusion guard: MONDO:0014562 carries the structured gene
  relationship RO:0004003 -> HGNC:19693 (COQ4) and the xref OMIM:616276, both of
  which were verified with OAK before curation. The disease MIM number is
  616276; published papers cite differing MIM numbers for the COQ4 gene itself,
  so the disease number should be taken from the MONDO xref rather than from
  narrative text.
  This entry is mechanistically distinct from the other neonatal mitochondrial
  cardiomyopathies in or entering the knowledge base:
  Cardiomyopathy-Hypotonia-Lactic_Acidosis_Syndrome (SLC25A3) is a
  mitochondrial phosphate-carrier defect, and MTO1 and MRPL44 deficiency
  (curated concurrently in open pull requests, not yet merged at the time of
  writing) are defects of mitochondrial translation; COQ4 disease is a defect of
  coenzyme Q10 biosynthesis.
  Epidemiology sourcing: an Orphanet prevalence class was not used because the
  local Orphadata snapshot could not be refreshed (known repository issue), so
  the prevalence records below use qualitative bands.
inheritance:
- name: Autosomal Recessive
  description: >
    COQ10D7 is inherited in an autosomal recessive pattern; affected individuals
    carry homozygous or compound heterozygous COQ4 variants and heterozygous
    parents are unaffected. Heterozygous carriers of COQ4 nonsense alleles are
    healthy, arguing against haploinsufficiency as the disease mechanism.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in COQ4 cause an autosomal recessive lethal neonatal
      mitochondrial encephalomyopathy associated with a founder mutation in the
      Ashkenazi Jewish population.
    explanation: >-
      States the autosomal recessive mode of inheritance for the neonatal COQ4
      phenotype.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All these individuals carried homozygous or compound-heterozygous
      mutations, clearly indicating that the resulting disease is an
      autosomal-recessive trait.
    explanation: >-
      Biallelic (homozygous or compound heterozygous) genotypes in all affected
      subjects establish recessive inheritance.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Given that the heterozygous parents carrying the nonsense mutations are
      alive and well, it is unlikely that COQ4 haploinsufficiency is pathogenic
    explanation: >-
      Healthy heterozygous parents argue that a single loss-of-function allele
      is insufficient to cause disease, supporting a strictly recessive model.
  - reference: PMID:28125198
    reference_title: "Primary Coenzyme Q(10) Deficiency Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inform genetic counseling of family members of an individual with primary
      CoQ10 deficiency.
    explanation: >-
      The GeneReviews overview treats genetic counselling of family members as a
      core management task, which follows from the autosomal recessive
      inheritance and the 25% sibling recurrence risk; PARTIAL because the
      abstract states the counselling objective rather than the mode of
      inheritance directly.
classifications:
  mechanistic_category:
  - classification_value: mitochondrial disease
    evidence:
    - reference: PMID:31396399
      reference_title: "Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Primary coenzyme Q10 deficiency-7 (COQ10D7) is a rare mitochondrial
        disease caused by biallelic mutations in COQ4.
      explanation: >-
        COQ10D7 is explicitly classified as a mitochondrial disease caused by
        biallelic COQ4 variants.
pathophysiology:
- name: COQ4 Loss of Function and CoQ Synthome Destabilization
  biological_scale: MOLECULAR
  description: >
    Biallelic COQ4 variants reduce or abolish COQ4 protein. COQ4 has no
    demonstrated catalytic step of its own; the yeast orthologue acts as a
    structural scaffold stabilizing the multiheteromeric complex that assembles
    most of the CoQ biosynthetic enzymes, so loss of COQ4 destabilizes the whole
    biosynthetic machine. Missense, nonsense, frameshift and in-frame deletion
    alleles have all been reported, and patient fibroblasts show markedly
    reduced COQ4 protein levels. Note that the molecular-function term below is
    a curator inference: the cited source states that the precise catalytic
    function of human COQ4 is unknown and describes it as playing a structural,
    complex-stabilizing role, for which the adaptor-activity term is the closest
    available GO proxy.
  genes:
  - preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  molecular_functions:
  - preferred_term: protein-macromolecule adaptor activity
    term:
      id: GO:0030674
      label: protein-macromolecule adaptor activity
    modifier: DECREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The precise function of human COQ4 is not known, but it seems to play a
      structural role in stabilizing a multiheteromeric complex that contains
      most of the CoQ10 biosynthetic enzymes.
    explanation: >-
      Establishes the scaffolding role of COQ4 in the CoQ10 biosynthetic
      complex, the function lost in COQ10D7.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      a drastic decrease in the amount of COQ4 was detected by immunoblot
      analysis in S1, S4, and S5 fibroblasts
    explanation: >-
      Patient-derived fibroblasts show loss of COQ4 protein, confirming the
      variants are loss-of-function at the protein level.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      oxidative growth, strongly impaired in strains lacking COQ4, was corrected
      by expression of human wild-type COQ4 cDNA but failed to be corrected by
      expression of COQ4 cDNAs with any of the mutations identified in affected
      subjects
    explanation: >-
      Yeast complementation assays demonstrate that every patient allele causes
      loss of COQ4 function.
  downstream:
  - target: Coenzyme Q10 Biosynthetic Failure
    causal_link_type: DIRECT
    description: >
      Destabilization of the CoQ biosynthetic complex blocks endogenous CoQ10
      production.
- name: Coenzyme Q10 Biosynthetic Failure
  biological_scale: MOLECULAR
  description: >
    Loss of COQ4 collapses de novo CoQ10 synthesis. Because dietary contribution
    to cellular CoQ10 is negligible, tissue CoQ10 falls steeply: muscle and
    fibroblast CoQ10 are severely reduced in affected neonates. The pathway
    intermediate 6-demethoxyubiquinone accumulates in patient cells, a metabolic
    signature of COQ4 deficiency that localises the block within the pathway.
  biological_processes:
  - preferred_term: ubiquinone biosynthetic process
    term:
      id: GO:0006744
      label: ubiquinone biosynthetic process
    modifier: DECREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All available specimens from affected subjects showed reduced amounts of
      CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex
      activities.
    explanation: >-
      Directly documents reduced tissue CoQ10 as the biochemical consequence of
      COQ4 loss.
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Experiments revealed significantly decreased COQ4 protein levels, reduced
      levels of cellular CoQ10 and elevated levels of the metabolic intermediate
      6-demethoxyubiquinone.
    explanation: >-
      Patient fibroblast studies link COQ4 protein loss to reduced CoQ10 and
      accumulation of the upstream intermediate 6-demethoxyubiquinone.
  downstream:
  - target: Impaired CoQ10-Dependent Respiratory Chain Electron Transfer
    causal_link_type: DIRECT
    description: >
      Depletion of the mobile electron carrier interrupts electron flow from
      complexes I and II to complex III.
- name: Impaired CoQ10-Dependent Respiratory Chain Electron Transfer
  biological_scale: CELLULAR
  description: >
    CoQ10 is the lipophilic mobile carrier that shuttles electrons from complex
    I and complex II (and from other flavoprotein dehydrogenases) to complex
    III. Its depletion produces a combined, CoQ10-specific respiratory-chain
    lesion: the coupled complex I+III and complex II+III activities fall while
    the individual complexes are often preserved, which is the biochemical
    fingerprint that distinguishes a CoQ10 biosynthesis defect from an assembly
    defect of a single complex. Maximal respiratory rates are reduced in patient
    fibroblasts.
  biological_processes:
  - preferred_term: electron transport chain
    term:
      id: GO:0022900
      label: electron transport chain
    modifier: DECREASED
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CoQ10 is an essential component of the electron transport chain (ETC),
      where it shuttles electrons from complex I or II to complex III.
    explanation: >-
      Establishes the electron-carrier role of CoQ10 whose loss produces the
      combined respiratory-chain defect.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the combined activities of CoQ10-dependent complexes i.e.,
      rotenone-sensitive NADH cytochrome c reductase (complex I + III) and
      succinate-cytochrome c reductase (complex II + III) were also found to be
      significantly reduced, whereas the activities of other complexes were
      essentially comparable to those found in normal controls
    explanation: >-
      Demonstrates the selective loss of coupled CoQ10-dependent segments with
      preserved individual complexes, the hallmark of CoQ10 deficiency.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we detected that maximal respiratory rates were lower in S1, S4, and S5
      fibroblasts than in control cells
    explanation: >-
      Respirometry in patient fibroblasts confirms a functional bioenergetic
      deficit.
  downstream:
  - target: Bioenergetic Failure of High-Energy-Demand Tissues
    causal_link_type: DIRECT
    description: >
      Loss of oxidative ATP synthesis preferentially injures tissues with the
      highest energy demand and CoQ10 content.
- name: Bioenergetic Failure of High-Energy-Demand Tissues
  biological_scale: TISSUE
  description: >
    Organs with the highest oxidative workload - in the cited source the heart,
    kidneys and brain - carry the highest CoQ10 concentrations and fail first.
    In the neonatal COQ4 phenotype the injury falls on heart, brain and skeletal
    muscle, with renal function repeatedly reported as spared, distinguishing
    COQ4 from the renal-predominant COQ2/COQ6/COQ8B forms. The fulminant course
    of the neonatal form can mask multisystem involvement, so individual infants
    may appear predominantly cardiac or predominantly neurological. The specific
    cardiac and neural tissue lesions produced are curated under
    `histopathology`.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: mitochondrial ATP synthesis coupled electron transport
    term:
      id: GO:0042775
      label: mitochondrial ATP synthesis coupled electron transport
    modifier: DECREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      organs with the highest energy requirements, such as the heart, kidneys,
      and brain, have the highest CoQ10 concentrations
    explanation: >-
      Explains the tissue selectivity of CoQ10 deficiency towards
      high-energy-demand organs; this is a review-level background assertion in
      the discussion rather than a patient observation.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No evidence of hepatic or renal impairment was observed.
    explanation: >-
      Supports renal and hepatic sparing in the index neonate, the feature that
      separates COQ4 disease from the renal-predominant CoQ10 deficiencies.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no evidence of renal dysfunction, transaminitis or liver
      synthetic dysfunction.
    explanation: >-
      Independently confirms renal and hepatic sparing in a COQ4-deficient
      infant.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The variable specificity of organ failure (e.g., heart versus brain) in
      the neonatal cases of our cohort could be due to the fulminant course of
      the disease, which prevented the deployment of multisystem involvement.
    explanation: >-
      Accounts for the apparently organ-restricted presentations within a
      systemic bioenergetic disorder.
  downstream:
  - target: Rapidly Progressive Lactic Acidosis and Multiorgan Failure
    causal_link_type: DIRECT
    description: >
      Blocked oxidative metabolism forces anaerobic glycolysis with lactate
      accumulation and precipitates multiorgan failure.
- name: Rapidly Progressive Lactic Acidosis and Multiorgan Failure
  biological_scale: ORGANISM
  description: >
    With oxidative phosphorylation blocked, pyruvate is shunted to lactate and
    blood lactate rises steeply in the first hours to days of life. Severe
    lactic acidosis in combination with cardiac and respiratory failure
    determines the fatal outcome of the classic neonatal presentation.
  biological_processes:
  - preferred_term: lactate metabolic process
    term:
      id: GO:0006089
      label: lactate metabolic process
    modifier: INCREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Rapidly progressive, severe lactic acidosis was a common feature in all
      four affected newborn subjects and is likely to have determined their
      fatal outcome.
    explanation: >-
      Directly links the lactic acidosis of the neonatal COQ4 phenotype to
      mortality.
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperlactatemia was one of the most common manifestations, accounting for
      75% of cases (18/24).
    explanation: >-
      Quantifies hyperlactatemia across the published neonatal-onset COQ4
      cohort.
phenotypes:
- name: Neonatal Hypotonia
  category: Neurologic
  description: >
    Profound generalised hypotonia is present from the first day of life and was
    the single most consistent finding in the defining neonatal COQ4 cohort,
    seen in all six patients. Areflexia may accompany it.
  phenotype_term:
    preferred_term: Neonatal hypotonia
    term:
      id: HP:0001319
      label: Neonatal hypotonia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Hypotonia was present in 6/6 neonatal COQ4 patients, supporting a
      VERY_FREQUENT (80-100%) frequency band.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two unrelated individuals presented with severe hypotonia, bradycardia,
      respiratory insufficiency, and heart failure
    explanation: >-
      Independent cohort confirming severe neonatal hypotonia as a presenting
      feature.
- name: Encephalopathy
  category: Neurologic
  description: >
    Neonatal encephalopathy with EEG abnormalities is a defining feature and
    was present in all four patients in whom EEG was performed in the original
    cohort of six. It frequently evolves into an epileptic encephalopathy.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  frequency: FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Encephalopathy with EEG abnormalities was found in 4/4 patients assessed
      by EEG. Because the denominator of the whole cohort is 6, the conservative
      intention-to-ascertain estimate is 4/6 (67%), which maps to FREQUENT
      rather than VERY_FREQUENT.
- name: Epileptic Encephalopathy
  category: Neurologic
  description: >
    A severe myoclonic epileptic encephalopathy can ensue within hours of birth,
    and the early-onset COQ4 pattern is characterised by neonatal brain
    anomalies with epileptic encephalopathy. Seizures are frequently
    pharmacoresistant.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      two sisters showed antenatal cerebellar hypoplasia, neonatal
      respiratory-distress syndrome, and epileptic encephalopathy
    explanation: >-
      Documents neonatal epileptic encephalopathy in COQ4-mutant sisters.
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      type 1: early-onset phenotype with neonatal brain anomalies and epileptic
      encephalopathy
    explanation: >-
      The large COQ4 cohort defines the early-onset (neonatal) pattern by brain
      anomalies plus epileptic encephalopathy.
- name: Neonatal Seizures
  category: Neurologic
  description: >
    Seizures beginning in the neonatal period were reported in half of the
    patients in the defining cohort and can be refractory to multi-drug therapy.
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  frequency: FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Neonatal seizures in 3/6 patients (50%) maps to the FREQUENT (30-79%)
      band.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure management was initially acceptable, but the patient eventually
      became refractory to multi-drug therapy (phenobarbital, topiramate,
      clobazam).
    explanation: >-
      Illustrates the pharmacoresistant character of seizures in COQ4
      deficiency.
- name: Cerebellar Atrophy
  category: Neurologic
  description: >
    Cerebellar atrophy is a characteristic neuroimaging finding, present in four
    of five imaged neonates in the defining cohort.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Cerebellar atrophy in 4/5 imaged patients (80%) supports the
      VERY_FREQUENT band.
- name: Antenatal Cerebellar Hypoplasia
  category: Neurologic
  description: >
    Cerebellar hypoplasia can be detected on prenatal organ screening as early
    as the 20th week of gestation, so the structural brain lesion is already
    established before birth; recurrence in a sibling prompted the prenatal
    diagnosis in one reported family.
  phenotype_term:
    preferred_term: Cerebellar hypoplasia
    term:
      id: HP:0001321
      label: Cerebellar hypoplasia
    onset:
      onset_category: ANTENATAL
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Performed at the 20th week of gestation, prenatal organ screening of S3
      revealed a suspected malformation of the cerebellum.
    explanation: >-
      Documents antenatal detection of the cerebellar malformation at 20 weeks
      gestation.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      two sisters showed antenatal cerebellar hypoplasia, neonatal
      respiratory-distress syndrome, and epileptic encephalopathy
    explanation: >-
      Confirms antenatal cerebellar hypoplasia in both affected sisters.
- name: Cardiomyopathy
  category: Cardiovascular
  description: >
    Cardiomyopathy was present in five of six patients in the defining neonatal
    cohort. With encephalopathy and respiratory distress it is one of the three
    features that give the disorder its name. The reported 5/6 count is for
    cardiomyopathy generically, so the frequency band is asserted at this
    generic level; the hypertrophic subtype is curated separately below.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Cardiomyopathy in 5/6 patients (83%) supports the VERY_FREQUENT band at
      the generic cardiomyopathy level.
- name: Hypertrophic Cardiomyopathy
  category: Cardiovascular
  description: >
    Where the cardiomyopathy has been characterised it is most often
    hypertrophic, with biventricular hypertrophy at autopsy, and it can be
    detected antenatally by fetal ultrasound. No frequency band is asserted
    because the published counts distinguishing the hypertrophic subtype from
    cardiomyopathy generally are not available in the cached sources.
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pregnancy was complicated by severe intrauterine growth delay and
      ultrasound-documented hypertrophic cardiomyopathy.
    explanation: >-
      Specifies the hypertrophic subtype and its antenatal detectability.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we report novel mutations in the COQ4 gene, which were identified in
      an infant with profound mitochondrial disease presenting with perinatal
      seizures, hypertrophic cardiomyopathy and severe muscle CoQ10 deficiency.
    explanation: >-
      Independent report confirming hypertrophic cardiomyopathy with severe
      muscle CoQ10 deficiency.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Biventricular hypertrophy was observed by echocardiogram.
    explanation: >-
      Echocardiographic confirmation of biventricular hypertrophy in an affected
      infant.
- name: Neonatal Respiratory Distress
  category: Respiratory
  description: >
    Neonatal respiratory-distress syndrome is one of the three cardinal features
    named in the disorder; respiratory insufficiency requiring intubation on the
    first day of life is typical.
  phenotype_term:
    preferred_term: Neonatal respiratory distress
    term:
      id: HP:0002643
      label: Neonatal respiratory distress
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      two sisters showed antenatal cerebellar hypoplasia, neonatal
      respiratory-distress syndrome, and epileptic encephalopathy
    explanation: >-
      Documents neonatal respiratory distress syndrome in COQ4-mutant neonates.
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical findings include hypotonia, seizures, respiratory
      distress, and cardiomyopathy.
    explanation: >-
      A review of published COQ10D7 cases lists respiratory distress among the
      common findings.
- name: Respiratory Insufficiency
  category: Respiratory
  description: >
    Respiratory insufficiency at or shortly after birth, often with apnoea
    requiring intubation, accompanies the profound hypotonia.
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two unrelated individuals presented with severe hypotonia, bradycardia,
      respiratory insufficiency, and heart failure
    explanation: >-
      Respiratory insufficiency is documented as a presenting neonatal feature.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      she became apnoeic and was intubated as a result of respiratory failure
    explanation: >-
      Illustrates first-day-of-life respiratory failure requiring ventilation.
- name: Bradycardia
  category: Cardiovascular
  description: >
    Bradycardia was a presenting sign in two unrelated neonates and recurred in
    an affected sibling who died at birth.
  phenotype_term:
    preferred_term: Bradycardia
    term:
      id: HP:0001662
      label: Bradycardia
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two unrelated individuals presented with severe hypotonia, bradycardia,
      respiratory insufficiency, and heart failure
    explanation: >-
      Bradycardia is documented as a neonatal presenting sign.
- name: Feeding Difficulties
  category: Gastrointestinal
  description: >
    Poor feeding and feeding difficulties have been reported as presenting
    complaints in infants who survive the immediate neonatal period, and
    gastroesophageal reflux severe enough to require fundoplication has been
    described. No frequency band is asserted because the available cached
    sources are individual case reports.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 1-year-old male was admitted to our clinic with complaints of hypotonia,
      seizures, and feeding difficulties.
    explanation: >-
      Feeding difficulties are a presenting complaint in a molecularly confirmed
      COQ10D7 patient.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional problems included gastroesophageal reflux requiring
      fundoplication
    explanation: >-
      Documents severe reflux requiring surgical management in COQ4 deficiency.
- name: Lactic Acidosis
  category: Metabolic
  description: >
    Severe, rapidly progressive lactic acidosis is the biochemical hallmark of
    the neonatal presentation.
  phenotype_term:
    preferred_term: Lactic acidosis
    term:
      id: HP:0003128
      label: Lactic acidosis
  frequency: FREQUENT
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical findings included hypotonia (6/6), encephalopathy with EEG
      abnormalities (4/4), neonatal seizures (3/6), cerebellar atrophy (4/5),
      cardiomyopathy (5/6) and lactic acidosis (4/6).
    explanation: >-
      Lactic acidosis in 4/6 patients (67%) maps to the FREQUENT (30-79%) band.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Rapidly progressive, severe lactic acidosis was a common feature in all
      four affected newborn subjects and is likely to have determined their
      fatal outcome.
    explanation: >-
      Confirms severe, rapidly progressive lactic acidosis in the neonatal
      subgroup.
- name: Hearing Impairment
  category: Sensory
  description: >
    Bilateral hearing loss has been reported in an infant with COQ4 deficiency
    who survived beyond the immediate neonatal period. The source does not
    characterise the loss audiometrically, so the generic hearing-impairment
    term is used rather than a sensorineural subtype.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional problems included gastroesophageal reflux requiring
      fundoplication, delayed visual maturation without structural abnormality
      of the eyes, bilateral hearing loss, profound hypotonia and absence of
      development.
    explanation: >-
      Bilateral hearing loss is documented in a COQ4-deficient infant.
- name: Global Developmental Delay
  category: Neurodevelopmental
  description: >
    Infants who survive the neonatal period show severe developmental
    impairment; one reported infant had absence of development, and severe
    cognitive and/or developmental delay is listed among the typical
    manifestations of COQ4-related disease.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      profound hypotonia and absence of development
    explanation: >-
      Documents complete absence of developmental progress in a COQ4-deficient
      infant.
  - reference: PMID:37948995
    reference_title: "Epilepsy and Coenzyme Q10 deficiency with COQ4 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical manifestations include early pharmacoresistant seizure, severe
      cognition and/or developmental delay, dystonia, ataxia, and spasticity.
    explanation: >-
      Lists severe cognitive and developmental delay among the typical
      manifestations of COQ4-related CoQ10 deficiency.
- name: Dystonia
  category: Neurologic
  description: >
    Dystonia is listed among the typical manifestations of COQ4-related CoQ10
    deficiency. It belongs to the survivor phase of the disorder rather than the
    first days of life, and the citing review spans the whole COQ4 spectrum
    (prenatal to adult onset), so no frequency band is asserted for the
    neonatal-onset subset curated here.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:37948995
    reference_title: "Epilepsy and Coenzyme Q10 deficiency with COQ4 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical manifestations include early pharmacoresistant seizure, severe
      cognition and/or developmental delay, dystonia, ataxia, and spasticity.
    explanation: >-
      Names dystonia among the typical manifestations of COQ4-related CoQ10
      deficiency; PARTIAL because the review describes the full COQ4 spectrum
      rather than the neonatal-onset form specifically.
- name: Ataxia
  category: Neurologic
  description: >
    Ataxia is listed among the typical manifestations of COQ4-related CoQ10
    deficiency, consistent with the prominent cerebellar involvement
    (hypoplasia and atrophy) seen in this disorder. As with dystonia, it is a
    survivor-phase feature drawn from a whole-spectrum review, so no frequency
    band is asserted.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:37948995
    reference_title: "Epilepsy and Coenzyme Q10 deficiency with COQ4 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical manifestations include early pharmacoresistant seizure, severe
      cognition and/or developmental delay, dystonia, ataxia, and spasticity.
    explanation: >-
      Names ataxia among the typical manifestations of COQ4-related CoQ10
      deficiency; PARTIAL because the review describes the full COQ4 spectrum
      rather than the neonatal-onset form specifically.
- name: Spasticity
  category: Neurologic
  description: >
    Spasticity is listed among the typical manifestations of COQ4-related CoQ10
    deficiency and is a survivor-phase feature; the profound hypotonia of the
    neonatal presentation is the earlier and distinct motor finding. Drawn from
    a whole-spectrum review, so no frequency band is asserted.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:37948995
    reference_title: "Epilepsy and Coenzyme Q10 deficiency with COQ4 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The typical manifestations include early pharmacoresistant seizure, severe
      cognition and/or developmental delay, dystonia, ataxia, and spasticity.
    explanation: >-
      Names spasticity among the typical manifestations of COQ4-related CoQ10
      deficiency; PARTIAL because the review describes the full COQ4 spectrum
      rather than the neonatal-onset form specifically.
- name: Nystagmus
  category: Sensory
  description: >
    Bilateral horizontal nystagmus with inability to maintain eye contact was
    found on examination in a molecularly confirmed COQ10D7 patient, alongside
    the delayed visual maturation reported elsewhere in the literature.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A physical examination revealed microcephaly, a high palate, poor feeding,
      weak crying, hypotonia, bilateral horizontal nystagmus, and inability to
      maintain eye contact.
    explanation: >-
      Documents bilateral horizontal nystagmus on examination in a molecularly
      confirmed COQ10D7 patient.
- name: Visual Impairment
  category: Sensory
  description: >
    Delayed visual maturation without a structural ocular abnormality has been
    reported, indicating a central rather than ophthalmic basis for the visual
    deficit.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      delayed visual maturation without structural abnormality of the eyes
    explanation: >-
      Documents visual impairment of central origin in a COQ4-deficient infant.
- name: Microcephaly
  category: Neurologic
  description: >
    Acquired microcephaly with cerebral volume loss has been documented on
    serial MRI in an affected infant, and microcephaly was a presenting physical
    finding in a molecularly confirmed COQ10D7 patient.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Subsequent MRI at 10 weeks showed microcephaly with volume loss and
      increasing prominence of lactate peaks.
    explanation: >-
      Serial neuroimaging documents acquired microcephaly with cerebral volume
      loss.
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A physical examination revealed microcephaly, a high palate, poor feeding,
      weak crying, hypotonia, bilateral horizontal nystagmus, and inability to
      maintain eye contact.
    explanation: >-
      Microcephaly on clinical examination in a molecularly confirmed COQ10D7
      patient.
- name: Dysmorphic Features
  category: Craniofacial
  description: >
    Dysmorphic features accompany the neurological presentation in some
    patients; reported findings include dolichocephaly, periorbital edema, long
    eyelashes and a high palate. The reporting authors argue COQ10D7 belongs in
    the differential of infants presenting with combined neurological and
    dysmorphic manifestations.
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A physical examination revealed hypotonia, a dolichocephaly, periorbital
      edema, and long eyelashes.
    explanation: >-
      Enumerates the dysmorphic findings in a molecularly confirmed COQ10D7
      patient.
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary Coenzyme Q10 Deficiency-7 should be considered in the differential
      diagnosis of infants presenting with neurological and dysmorphic
      manifestations.
    explanation: >-
      The authors' conclusion establishes dysmorphism as a recognised part of the
      COQ10D7 presentation.
- name: Intrauterine Growth Retardation
  category: Growth
  description: >
    Severe intrauterine growth restriction, often with preterm delivery, is a
    recurrent antenatal manifestation; prenatal abnormalities are significantly
    more frequent among preterm than full-term affected infants.
  phenotype_term:
    preferred_term: Intrauterine growth retardation
    term:
      id: HP:0001511
      label: Intrauterine growth retardation
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pregnancy was complicated by severe intrauterine growth delay and
      ultrasound-documented hypertrophic cardiomyopathy.
    explanation: >-
      Documents severe intrauterine growth restriction in an affected pregnancy.
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence of prenatal abnormalities in preterm infants was
      significantly higher than that in full-term infants (66.7% vs. 16.7%, P =
      0.02).
    explanation: >-
      Supports the antenatal-abnormality burden in preterm affected infants;
      indirect for growth restriction specifically, hence PARTIAL.
biochemical:
- name: Reduced tissue coenzyme Q10
  notes: >
    CoQ10 is severely reduced in skeletal muscle and in cultured skin
    fibroblasts from affected neonates. This is the defining biochemical
    abnormality and is measured by reversed-phase HPLC with electrochemical
    detection. The bound term covers the skeletal-muscle measurement; the
    parallel reduction in cultured fibroblasts has no distinct ontology term.
  biomarker_term:
    preferred_term: Decreased level of coenzyme Q10 in skeletal muscle
    term:
      id: HP:0034369
      label: Decreased level of coenzyme Q10 in skeletal muscle
  presence: DECREASED
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All available specimens from affected subjects showed reduced amounts of
      CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex
      activities.
    explanation: >-
      Reduced tissue CoQ10 is documented across all available patient specimens.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The levels of CoQ10 in autopsied skeletal muscle (6.9 μg/g tissue; normal
      range 19.6–46.8) and in skin fibroblasts (19.1 μg/mg protein; normal range
      45.4–65.7) were found to be severely reduced.
    explanation: >-
      Provides quantitative muscle and fibroblast CoQ10 values against
      laboratory reference ranges.
- name: Elevated 6-demethoxyubiquinone
  notes: >
    The CoQ biosynthetic intermediate 6-demethoxyubiquinone accumulates in
    patient-derived fibroblasts, providing a metabolic marker of COQ4
    deficiency.
    NEEDS TERM (NTR candidate): no `biomarker_term` is bound because searches of
    HPO and CHEBI in this repository's configured ontologies returned no term
    for 6-demethoxyubiquinone or its accumulation. A new-term request would be
    required to bind this marker.
  presence: INCREASED
  evidence:
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Experiments revealed significantly decreased COQ4 protein levels, reduced
      levels of cellular CoQ10 and elevated levels of the metabolic intermediate
      6-demethoxyubiquinone.
    explanation: >-
      Documents accumulation of 6-demethoxyubiquinone in COQ4-deficient cells.
- name: Increased circulating lactate concentration
  notes: >
    Blood lactate is markedly elevated in the classic neonatal presentation, and
    hyperlactatemia is among the most frequently reported laboratory
    abnormalities in the published neonatal cohort.
  biomarker_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  presence: INCREASED
  evidence:
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperlactatemia was one of the most common manifestations, accounting for
      75% of cases (18/24).
    explanation: >-
      Quantifies hyperlactatemia in 18 of 24 published neonatal COQ4 cases.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      her lactic acidosis rapidly worsened (blood lactate = 11.2–18.8 mM; n.v. <
      2)
    explanation: >-
      Gives measured blood lactate values against the laboratory normal value in
      an affected neonate.
- name: Reduced coupled complex I+III and II+III activities
  notes: >
    Spectrophotometric assay of the respiratory chain shows selective reduction
    of the CoQ10-dependent coupled reactions (rotenone-sensitive
    NADH-cytochrome c reductase, complex I+III; succinate-cytochrome c
    reductase, complex II+III) with relatively preserved activities of the
    individual complexes. Findings are variable between tissues and can be
    normal in some specimens, so a normal result does not exclude the diagnosis.
    The bound term is the generic decreased-respiratory-chain-activity concept;
    no ontology term distinguishes the coupled CoQ10-dependent segments
    (I+III, II+III) from the individual complexes, which is the pattern that
    actually discriminates a CoQ10 biosynthesis defect.
  biomarker_term:
    preferred_term: Decreased activity of mitochondrial respiratory chain
    term:
      id: HP:0008972
      label: Decreased activity of mitochondrial respiratory chain
  presence: DECREASED
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      the combined activities of CoQ10-dependent complexes i.e.,
      rotenone-sensitive NADH cytochrome c reductase (complex I + III) and
      succinate-cytochrome c reductase (complex II + III) were also found to be
      significantly reduced, whereas the activities of other complexes were
      essentially comparable to those found in normal controls
    explanation: >-
      Demonstrates the selective coupled-activity defect diagnostic of CoQ10
      deficiency.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical heterogeneity was accompanied by an equally striking variability
      of the biochemical findings, which ranged from multiple (S1 and S5) to
      isolated (S2 and S3) ETC defects in muscle and fibroblasts to hardly any
      detectable defect at all (S4).
    explanation: >-
      Documents the variability of respiratory-chain findings, which limits the
      sensitivity of enzymology as a diagnostic test.
histopathology:
- name: Biventricular Cardiac Hypertrophy with Abnormal Cardiomyocyte Mitochondria
  description: >
    Autopsy of an affected infant showed marked biventricular cardiac
    hypertrophy; electron microscopy of cardiomyocyte mitochondria showed
    swollen organelles with loss of cristae and unusual semi-circular cristae
    arrangements, while kidney and liver mitochondria were unremarkable -
    consistent with tissue-selective bioenergetic injury.
  evidence:
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At autopsy, there was marked bi-ventricular cardiac hypertrophy. EM
      studies of cardiomyocytes mitochondria showed swollen mitochondria with
      loss of cristae and some mitochondria with semi-circular arrangements of
      cristae
    explanation: >-
      Describes the cardiac ultrastructural pathology of COQ4 deficiency.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Light microscopy and EM studies of mitochondria in the kidney and liver
      were unremarkable.
    explanation: >-
      Confirms the tissue selectivity of the ultrastructural injury (heart
      affected, kidney and liver spared).
- name: Neuronal Loss with Reactive Astrocytosis and Cerebellar-Brainstem Hypoplasia
  description: >
    Neuropathology in the defining cohort showed neuron loss with reactive
    astrocytosis in one patient and cerebellar and brainstem hypoplasia with
    microdysgenesis in another, matching the neuroimaging finding of cerebellar
    atrophy.
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autopsy findings in two patients revealed neuron loss and reactive
      astrocytosis or cerebellar and brainstem hypoplasia and microdysgenesis.
    explanation: >-
      Documents the neuropathological substrate of the encephalomyopathy.
genetic:
- name: COQ4 biallelic pathogenic variants
  notes: >
    COQ10D7 is caused by biallelic (homozygous or compound heterozygous)
    pathogenic variants in COQ4, encoding a 265-amino-acid mitochondrial protein
    peripherally associated with the matrix side of the inner membrane.
    Missense, nonsense, frameshift and in-frame deletion alleles have all been
    described.
  gene_term:
    preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:31396399
    reference_title: "Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary coenzyme Q10 deficiency-7 (COQ10D7) is a rare mitochondrial
      disease caused by biallelic mutations in COQ4.
    explanation: >-
      Establishes COQ4 as the causal gene for COQ10D7, the entity curated here.
  - reference: PMID:38353291
    reference_title: "Two Turkish patients with Primary Coenzyme Q10 Deficiency-7: case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary Coenzyme Q10 Deficiency-7 (OMIM 616276) results from bi-allelic
      pathogenic variants in the COQ4 gene.
    explanation: >-
      Independently ties the OMIM 616276 entity - the xref of MONDO:0014562 - to
      biallelic COQ4 variants, confirming gene identity.
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      codes for a ubiquitously expressed 265-amino-acid protein that is
      peripherally associated with the mitochondrial inner membrane on the
      matrix side
    explanation: >-
      Describes the COQ4 gene product and its submitochondrial localisation.
- name: Ashkenazi Jewish founder allele
  notes: >
    A COQ4 missense allele was found in the homozygous state in two unrelated
    Ashkenazi Jewish probands, identifying a founder mutation in that
    population.
  gene_term:
    preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One mutation was found in a homozygous state in two unrelated Ashkenazi
      Jewish probands.
    explanation: >-
      Identifies the Ashkenazi Jewish founder allele.
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in COQ4 cause an autosomal recessive lethal neonatal
      mitochondrial encephalomyopathy associated with a founder mutation in the
      Ashkenazi Jewish population.
    explanation: >-
      Explicitly designates the variant as an Ashkenazi Jewish founder mutation.
- name: c.370G>A p.(Gly124Ser) East Asian founder allele
  notes: >
    The COQ4 variant c.370G>A, p.(Gly124Ser) (NM_016035.5) is a founder allele
    in southern Chinese populations and is the most commonly detected pathogenic
    COQ4 variant in Asian patients, so its regional frequency raises the
    pre-test probability of COQ10D7 in a neonate from that background. Patients
    carrying it show intermediate disease severity with multisystem dysfunction.
  gene_term:
    preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:31396399
    reference_title: "Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also identify a founder mutation COQ4 (NM_016035.5): c.370G>A,
      p.(Gly124Ser) for COQ10D7, suggesting a higher chance of occurrence in the
      southern Chinese.
    explanation: >-
      Identifies and names the southern Chinese founder allele.
  - reference: PMID:37948995
    reference_title: "Epilepsy and Coenzyme Q10 deficiency with COQ4 variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among those patients, c.370G > A variant is the most common pathogenic
      variant detected, especially in Asian population.
    explanation: >-
      Confirms c.370G>A as the predominant COQ4 allele in Asian patients.
  - reference: PMID:35154243
    reference_title: "Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with the East Asian-specific c.370G > A variant displays
      intermediate disease severity with multi-systemic dysfunction, which is
      between that of the patients with variants in exons 1-4 and 5-7.
    explanation: >-
      Places the East Asian founder allele at intermediate severity within the
      exon-dependent gradient.
- name: Exon-dependent genotype-phenotype gradient
  notes: >
    A proposed exon-dependent correlation stratifies COQ10D7: variants in exons
    1-4 associate with later onset, CoQ10 responsiveness and longer survival,
    whereas variants in exons 5-7 associate with early onset, unresponsiveness
    to CoQ10 and early death - the genotype class that produces the neonatal
    phenotype curated here. This is an observational rule from a review rather
    than a validated predictor, and sex is not associated with severity.
  gene_term:
    preferred_term: COQ4
    term:
      id: hgnc:19693
      label: COQ4
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:35154243
    reference_title: "Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathogenic COQ4 variants in exons 1-4 are associated with less
      life-threating presentations, late onset, responsiveness to CoQ10 therapy,
      and a relatively long lifespan. In contrast, pathogenic COQ4 variants in
      exons 5-7 are associated with early onset, unresponsiveness to CoQ10
      therapy, and early death and are more fatal.
    explanation: >-
      States the exon-dependent genotype-phenotype gradient, placing the severe
      neonatal phenotype with exon 5-7 variants; PARTIAL because this is an
      observational correlation proposed in a narrative review, not a validated
      predictor.
  - reference: PMID:35154243
    reference_title: "Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sex is shown unlikely to be associated with disease severity.
    explanation: >-
      Excludes sex as a severity modifier; PARTIAL because it is a review-level
      observation rather than a powered analysis.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    The largest published series characterised 44 individuals from 36 families
    across all COQ4 phenotypes, of which the neonatal-onset form is a subset; a
    separate review aggregated 24 neonatal-onset cases. No population-based rate
    has been published, so a qualitative band is used.
  evidence:
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We characterised 44 individuals from 36 families with COQ4 deficiency (16
      newly described).
    explanation: >-
      The largest published COQ4 cohort totals 44 individuals, supporting an
      ultra-rare classification.
- population: Southern Chinese
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    A founder allele raises the regional occurrence in southern China; no
    quantitative population rate has been published.
  evidence:
  - reference: PMID:31396399
    reference_title: "Primary coenzyme Q10 deficiency-7: expanded phenotypic spectrum and a founder mutation in southern Chinese."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also identify a founder mutation COQ4 (NM_016035.5): c.370G>A,
      p.(Gly124Ser) for COQ10D7, suggesting a higher chance of occurrence in the
      southern Chinese.
    explanation: >-
      Supports a regionally elevated occurrence without a quantitative rate.
progression:
- phase: Antenatal
  notes: >
    Prenatal manifestations may include cerebellar malformation on second
    trimester organ screening, intrauterine growth restriction, fetal
    hypertrophic cardiomyopathy and preterm delivery.
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Performed at the 20th week of gestation, prenatal organ screening of S3
      revealed a suspected malformation of the cerebellum.
    explanation: >-
      Antenatal cerebellar malformation can be the earliest detectable sign.
- phase: Neonatal presentation
  age_range: First day of life
  notes: >
    Presentation is on the first day of life with hypotonia, encephalopathy,
    respiratory distress or insufficiency, cardiomyopathy and rising lactate.
  evidence:
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients were female, and presented on the first day of life, and died
      in the neonatal period or early infancy.
    explanation: >-
      Defines first-day-of-life onset for the neonatal COQ4 phenotype.
- phase: Neonatal and early infantile death
  notes: >
    Most affected neonates die within days to weeks; pooled mean survival across
    published neonatal-onset cases is about 60 days, and mortality did not
    differ significantly between Chinese and other reported cohorts.
  evidence:
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The survival time for the 24 cases was 60.0 ± 98.0 days (95% confidence
      interval CI: 0-252.0 days).
    explanation: >-
      Quantifies survival across 24 published neonatal-onset COQ4 cases.
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no statistically significant difference in the mortality between
      Chinese (9/12, 75%) and other regions (11/12, 91.7%) (P = 0.27).
    explanation: >-
      Quantifies mortality in both reported geographic groups.
diagnosis:
- name: Whole exome sequencing
  description: >
    Molecular genetic testing, predominantly whole exome sequencing, is the
    principal route to diagnosis; twenty of twenty-four published
    neonatal-onset cases were diagnosed this way. Because the neonatal course is
    fulminant, a rapid genome-wide approach is required for the diagnosis to be
    actionable, and no pathognomonic blood, muscle or imaging biomarker exists.
  evidence:
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Twenty of the 24 cases were diagnosed by whole exome sequencing.
    explanation: >-
      Establishes exome sequencing as the dominant diagnostic modality.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An early genome-wide diagnostic approach is needed for expeditious
      diagnosis of CoQ10 biosynthesis disorder because our study demonstrates
      that there are no pathognomonic blood, muscle, or imaging biomarkers of
      these diseases.
    explanation: >-
      Justifies genome-wide testing as first-line by the absence of a
      pathognomonic biomarker.
  - reference: PMID:28125198
    reference_title: "Primary Coenzyme Q(10) Deficiency Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Provide an evaluation strategy to identify the genetic cause of primary
      CoQ10 deficiency in a proband.
    explanation: >-
      GeneReviews treats identifying the genetic cause in a proband as a defined
      evaluation strategy, which is the diagnostic pathway this entry models;
      PARTIAL because the abstract states the overview's aim rather than
      naming exome sequencing as the specific modality.
- name: Tissue coenzyme Q10 quantification and respiratory chain enzymology
  description: >
    Measurement of CoQ10 in skeletal muscle or cultured fibroblasts by
    reversed-phase HPLC with electrochemical detection confirms the biochemical
    deficiency, and coupled respiratory-chain assays show the CoQ10-dependent
    pattern. Mitochondrial functional verification is recommended alongside
    genetic testing in high-incidence regions.
  evidence:
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To improve the diagnostic rate, in addition to genetic testing,
      mitochondrial functional verification should be prioritized in southern
      China, where the incidence is relatively high.
    explanation: >-
      Recommends mitochondrial functional testing as a complement to genetic
      diagnosis.
  - reference: PMID:35154243
    reference_title: "Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biochemical analyses of the characteristic impairments in CoQ10
      biosynthesis and mitochondrial respiratory chain activity, as well as the
      phenotypic rescue of the CoQ10 treatment, are necessary to confirm the
      pathogenicity of suspicious variants
    explanation: >-
      Positions biochemical assays as necessary confirmation of variant
      pathogenicity.
treatments:
- name: High-Dose Oral Coenzyme Q10 Supplementation
  description: >
    Oral CoQ10 (ubiquinone/ubiquinol) supplementation is the only
    disease-directed therapy and is the rationale for urgent diagnosis, since
    cofactor deficiencies are among the very few mitochondrial disorders with a
    pharmacological treatment. Its benefit in the neonatal COQ4 phenotype is
    limited: response was insufficient in the largest COQ4 cohort, and in the
    published neonatal series only nine of twenty-four patients received CoQ10,
    although all four survivors had done so. In a specialist CoQ10-biosynthesis
    cohort, oral doses up to 70 mg/kg/day were needed to ameliorate neurologic
    features and 30 mg/kg/day reversed or prevented renal disease, but three
    children with neonatal-onset neurologic disease still died in early
    childhood despite high-dose CoQ10 from birth. Exogenous CoQ10 cannot fully
    bypass the biosynthetic block in established neonatal CNS disease, and
    families of infants with neonatal neurologic presentations should be
    counselled about the poor prognosis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: coenzyme Q10 supplementation
    term:
      id: NCIT:C15425
      label: Nutritional Supplementation
    therapeutic_agent:
    - preferred_term: coenzyme Q10
      term:
        id: CHEBI:46245
        label: coenzyme Q10
  target_mechanisms:
  - target: Coenzyme Q10 Biosynthetic Failure
    treatment_effect: BYPASSES
    description: >
      Exogenous CoQ10 attempts to supply the product that the disrupted
      biosynthetic complex can no longer make, bypassing the synthetic block
      rather than repairing it.
  evidence:
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Due to the insufficient clinical response to oral CoQ10 supplementation,
      alternative treatment strategies are warranted.
    explanation: >-
      Documents the limited efficacy of oral CoQ10 in COQ4 deficiency, tempering
      the treatment claim.
  - reference: PMID:39398416
    reference_title: "The Spectrum of clinical manifestations in newborns with the COQ4 mutation: case series and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only 9 patients received exogenous coenzyme Q10 treatment, and all the 4
      surviving patients received coenzyme Q10 supplementation.
    explanation: >-
      All survivors in the neonatal series received CoQ10, but the uncontrolled
      observation cannot establish efficacy, hence PARTIAL.
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mutations in genes involved in CoQ(10) biosynthesis cause primary CoQ(10)
      deficiency syndromes that can be treated with oral supplementation of
      ubiquinone.
    explanation: >-
      States the therapeutic rationale for oral ubiquinone across primary CoQ10
      deficiency as a class; INDIRECT because it is a background statement about
      the disorder group, not evidence of efficacy in the neonatal COQ4 form.
  - reference: PMID:28125198
    reference_title: "Primary Coenzyme Q(10) Deficiency Overview."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Review management of primary CoQ10 deficiency, including targeted
      pharmacologic treatment with high-dose oral CoQ10 supplementation and
      supportive treatment.
    explanation: >-
      GeneReviews identifies high-dose oral CoQ10 supplementation plus
      supportive treatment as the targeted management of primary CoQ10
      deficiency; PARTIAL because the abstract states the management framework
      without COQ4-specific outcome data.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We show that oral doses of CoQ10 up to 70 mg/kg/d were needed to
      ameliorate neurologic features.
    explanation: >-
      Sources the upper dosing range cited in the description.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also demonstrate that early diagnosis and treatment of CoQ10 deficiency
      with oral supplementation (30 mg/kg/d) can reverse renal manifestations
      and can completely prevent kidney disease over 10 years of follow-up.
    explanation: >-
      Sources the 30 mg/kg/day renal-protective dose cited in the description,
      and illustrates the organ-specific contrast with the neonatal neurologic
      form.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with genetically confirmed CoQ10 biosynthesis disorder should
      receive high-dose oral CoQ10 as soon as possible after presentation,
      regardless of genetic cause, to prevent disease progression, but parents
      of children with neonatal or infantile neurologic presentations should be
      counseled about the poor prognosis.
    explanation: >-
      Supports prompt high-dose CoQ10 while explicitly qualifying the poor
      prognosis of neonatal neurologic presentations.
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      3 children with neonatal-onset neurologic disease died in early childhood
      despite receiving high-dose oral CoQ10 from birth
    explanation: >-
      Directly refutes the expectation that high-dose CoQ10 from birth rescues
      the neonatal-onset neurologic phenotype.
- name: Idebenone
  description: >
    Idebenone, a synthetic short-chain CoQ10 analogue, has been used as an
    adjunct to control seizures in some patients with CoQ10 biosynthesis
    disorders when high-dose CoQ10 alone was insufficient. Evidence is limited
    to a retrospective single-centre cohort of CoQ10 biosynthesis disorders
    rather than a COQ4-specific study.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: idebenone
      term:
        id: CHEBI:31687
        label: idebenone
  target_mechanisms:
  - target: Impaired CoQ10-Dependent Respiratory Chain Electron Transfer
    treatment_effect: BYPASSES
    description: >
      Idebenone is a short-chain quinone that can shuttle electrons in the
      respiratory chain independently of endogenous CoQ10, so it acts on the
      electron-transfer node rather than on the biosynthetic block itself.
  evidence:
  - reference: PMID:39601013
    reference_title: "Clinical Features, Biochemistry, Imaging, and Treatment Response in a Single-Center Cohort With Coenzyme Q(10) Biosynthesis Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional idebenone was required to control seizures in some cases, and
      3 children with neonatal-onset neurologic disease died in early childhood
      despite receiving high-dose oral CoQ10 from birth.
    explanation: >-
      Documents adjunctive idebenone for seizure control in a CoQ10
      biosynthesis-disorder cohort; PARTIAL because the observation is
      uncontrolled and not COQ4-specific.
- name: Neonatal Intensive Supportive Care
  description: >
    Management of the neonatal presentation is otherwise supportive: mechanical
    ventilation for respiratory failure, inotropic support for cardiac failure
    (which was ineffective in the first reported COQ4 neonate, who died four
    hours after birth), management of lactic acidosis, and anti-epileptic
    therapy for often-refractory seizures. Given the very high mortality,
    palliative care and genetic counselling for recurrence risk are integral.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dobutamine infusion via an umbilical venous catheter was ineffective, and
      the baby died 4 hr after birth.
    explanation: >-
      Illustrates the failure of inotropic support in fulminant neonatal COQ4
      cardiac failure.
  - reference: PMID:28540186
    reference_title: "Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ(10) deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He was discharged on palliative measures but was readmitted six days later
      with profound acidosis and respiratory failure.
    explanation: >-
      Documents the palliative trajectory typical of severe COQ4 disease.
discussions:
- discussion_id: coq4_neonatal_coq10_nonresponse
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why does exogenous CoQ10 supplementation fail to rescue the neonatal COQ4
    phenotype when it can reverse renal disease in other primary CoQ10
    deficiencies?
  rationale: >-
    Oral CoQ10 is the only disease-directed therapy available, yet the neonatal
    COQ4 form responds poorly and children have died in early childhood despite
    high-dose CoQ10 from birth. Candidate explanations include inadequate tissue
    and mitochondrial delivery of the highly lipophilic molecule, irreversible
    antenatal injury already established at birth, and CoQ10-independent
    consequences of losing the COQ4 scaffold. Distinguishing these determines
    whether better-delivered analogues could help or whether the therapeutic
    window closes before birth.
  attaches_to:
  - "pathophysiology#Coenzyme Q10 Biosynthetic Failure"
  proposed_experiments:
  - experiment_id: coq4_mito_delivery_rescue
    name: Mitochondrial CoQ10 repletion with alternative formulations
    description: >-
      Measure mitochondrial CoQ10 repletion and respiratory-chain rescue in
      COQ4-patient fibroblasts and cardiomyocytes treated with conventional
      CoQ10 versus mitochondria-targeted or solubilised formulations.
  - experiment_id: coq4_prenatal_treatment_window
    name: Prenatal treatment window in a COQ4 model
    description: >-
      Determine in a COQ4 model whether prenatal initiation of CoQ10 or a
      bypass analogue prevents the cerebellar hypoplasia that is already present
      at birth in human patients.
  evidence:
  - reference: PMID:34656997
    reference_title: "Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Due to the insufficient clinical response to oral CoQ10 supplementation,
      alternative treatment strategies are warranted.
    explanation: >-
      The authors of the largest COQ4 cohort explicitly frame the treatment
      failure as an open problem.
- discussion_id: coq4_tissue_selectivity
  kind: KNOWLEDGE_GAP
  prompt: >-
    What determines whether a given COQ4 genotype produces a heart-dominant, a
    brain-dominant, or a milder later-onset phenotype?
  rationale: >-
    The same biosynthetic lesion yields strikingly different organ involvement
    and biochemical severity between patients, and respiratory-chain enzymology
    ranges from multiple defects to none at all. The proposed exon 1-4 versus
    exon 5-7 gradient is an observational rule that does not explain tissue
    selectivity, so the modifiers remain unknown.
  attaches_to:
  - "pathophysiology#Bioenergetic Failure of High-Energy-Demand Tissues"
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This biochemical diversity could be due to differences in individual
      adaptive responses to reduced CoQ10 availability or could reflect the
      striking tissue specificity observed in the clinical presentations, but at
      the moment, a mechanistic explanation for these observations is lacking.
    explanation: >-
      The authors state explicitly that a mechanistic explanation for the tissue
      selectivity is lacking.
- discussion_id: coq4_antenatal_developmental_lesion
  kind: KNOWLEDGE_GAP
  prompt: >-
    Is the antenatal cerebellar hypoplasia of COQ4 deficiency a developmental
    patterning failure, or simply prenatal bioenergetic degeneration of an
    already-formed cerebellum?
  rationale: >-
    The pathophysiology chain modelled in this entry is a postnatal bioenergetic
    cascade, but cerebellar malformation is detectable at the 20th week of
    gestation and autopsy shows olivopontocerebellar hypoplasia with
    microdysgenesis - findings suggesting disturbed development rather than
    degeneration alone. Whether CoQ10 has a developmental role in cerebellar
    morphogenesis beyond ATP supply is unresolved, and the answer bounds any
    therapeutic window, because a patterning failure completed in utero cannot
    be reversed by postnatal supplementation.
  attaches_to:
  - "pathophysiology#Bioenergetic Failure of High-Energy-Demand Tissues"
  proposed_experiments:
  - experiment_id: coq4_cerebellar_development_timecourse
    name: Developmental time course of cerebellar CoQ4 loss
    description: >-
      Track cerebellar progenitor proliferation, migration and foliation in a
      conditional COQ4-loss model across gestation to distinguish failed
      morphogenesis from degeneration of formed structures.
  evidence:
  - reference: PMID:25658047
    reference_title: "COQ4 mutations cause a broad spectrum of mitochondrial disorders associated with CoQ10 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An autopsy of the brain revealed severe olivopontocerebellar and thalamic
      hypoplasia and scattered cavitations in the white matter
    explanation: >-
      Hypoplasia and microdysgenesis rather than pure atrophy point to a
      developmental component that the modelled postnatal bioenergetic chain
      does not account for.
  - reference: PMID:26185144
    reference_title: "Mutations in COQ4, an essential component of coenzyme Q biosynthesis, cause lethal neonatal mitochondrial encephalomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autopsy findings in two patients revealed neuron loss and reactive
      astrocytosis or cerebellar and brainstem hypoplasia and microdysgenesis.
    explanation: >-
      Microdysgenesis is a developmental lesion, reinforcing the open question.
references:
- reference: PMID:28125198
  title: "Primary Coenzyme Q(10) Deficiency Overview."
  tags:
  - GeneReviews
📚

References & Deep Research

References

1
PMID:28125198
Primary Coenzyme Q(10) Deficiency Overview.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
COQ4-Related Neonatal Encephalomyopathy: Disease Characteristics Report
Edison Scientific Literature 12 citations 2026-08-01T18:51:32.672348

COQ4-Related Neonatal Encephalomyopathy: Disease Characteristics Report

Executive summary

COQ4-related neonatal encephalomyopathy is the severe, prenatal/neonatal end of primary coenzyme Q10 deficiency type 7 (COQ10D7), an autosomal-recessive mitochondrial disorder caused by biallelic pathogenic variants in COQ4. The defining biology is failure of mitochondrial coenzyme-Q biosynthesis, with reduced CoQ10, accumulation of the intermediate 6-demethoxyubiquinone (6-DMQ), impaired respiratory-chain electron transfer, and preferential injury to the developing brain, skeletal muscle, heart, and respiratory system. The neonatal phenotype commonly comprises prenatal brain abnormalities, profound hypotonia, epileptic encephalopathy, respiratory failure, feeding failure, lactic acidosis, cerebellar hypoplasia/atrophy, and cardiomyopathy. Prognosis is poor: a 2024 aggregation of 24 neonatal cases found mean survival of 60.0 ± 98.0 days and 20 deaths, although ascertainment and publication bias are substantial. Oral CoQ10 is used immediately because the disorder is biochemically actionable, but established neonatal CNS disease usually responds incompletely. (pan2024thespectrumof pages 1-2, laugwitz2022humancoq4deficiency pages 1-3, laugwitz2022humancoq4deficiency pages 8-10)

The most useful quantitative evidence is summarized below.

domain best quantitative finding interpretation source/date/DOI or PMID if available
Neonatal cohort size 24 neonatal-onset cases total (4 new + 20 literature cases) Best current neonatal-focused summary of COQ4 disease burden is still based on small case aggregation, underscoring rarity and likely ascertainment bias (pan2024thespectrumof pages 1-2) Pan et al., Front Pediatr (Sep 2024), doi:10.3389/fped.2024.1410133
Neonatal mortality/survival Mean survival 60.0 ± 98.0 days; mortality 75% in Chinese cases (9/12) and 91.7% in non-Chinese cases (11/12), P=0.27 Neonatal COQ4 disease has very poor short-term survival overall, with no statistically significant regional mortality difference in this review (pan2024thespectrumof pages 1-2) Pan et al., Front Pediatr (Sep 2024), doi:10.3389/fped.2024.1410133
Neonatal biochemical abnormality Hyperlactatemia in 75% (18/24) Elevated lactate is common and useful diagnostically, but not universal; absence of lactate elevation does not exclude disease (pan2024thespectrumof pages 1-2) Pan et al., Front Pediatr (Sep 2024), doi:10.3389/fped.2024.1410133
Neonatal genetic diagnosis 20/24 diagnosed by whole-exome sequencing WES is the dominant real-world diagnostic route for neonatal COQ4 disease (pan2024thespectrumof pages 1-2) Pan et al., Front Pediatr (Sep 2024), doi:10.3389/fped.2024.1410133
Prenatal risk signals Prenatal abnormalities more frequent in preterm than full-term infants: 66.7% vs 16.7%, P=0.02 Supports prenatal/perinatal disease onset in the severest neonatal presentations (pan2024thespectrumof pages 1-2) Pan et al., Front Pediatr (Sep 2024), doi:10.3389/fped.2024.1410133
Largest human cohort 44 individuals from 36 families; 23 variants identified COQ4 deficiency is clinically heterogeneous but now sufficiently characterized to define subtypes (laugwitz2022humancoq4deficiency pages 1-3) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Core phenotype frequencies Respiratory distress 24/34; feeding difficulties 20/28; hypertrophic cardiomyopathy 15/35; hyperlactataemia 22/31 Multisystem neonatal/infantile disease commonly affects brain, cardiorespiratory status, feeding, and metabolism (laugwitz2022humancoq4deficiency pages 7-8) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Neuroimaging frequencies Cerebral atrophy 18 patients; cerebellar atrophy 15/36; cerebellar hypoplasia 10 cases; stroke-like lesions 8 patients; delayed myelination in ~50% of MRI studies Neuroimaging often shows a mitochondrial encephalopathy pattern, with cerebellar involvement especially prominent in severe neonatal disease (laugwitz2022humancoq4deficiency pages 7-8, laugwitz2022humancoq4deficiency pages 10-12) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Clinical subtypes 3 patterns: type 1 neonatal brain anomalies/epileptic encephalopathy; type 2 stroke-like lesions; type 3 moderate stable disease Helps stratify prognosis: type 1 is most severe and often neonatal, type 3 relatively milder (laugwitz2022humancoq4deficiency pages 1-3, laugwitz2022humancoq4deficiency pages 10-12) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Survival in broader cohort Only 5/44 reached adulthood Confirms high childhood mortality, especially in early-onset encephalopathic forms (laugwitz2022humancoq4deficiency pages 8-10) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Treatment exposure and response CoQ10 given to 29 patients at 15–60 mg/kg/day; 16/29 no response; 12/29 limited improvement/stabilization Oral CoQ10 is widely used in practice but usually yields modest or absent neurologic benefit in COQ4 disease (laugwitz2022humancoq4deficiency pages 7-8) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Current treatment recommendation Oral CoQ10 should be started immediately in suspected CoQ biosynthesis disorders and titrated to at least 30 mg/kg/day after genetic confirmation; one COQ4 case also received idebenone 20 mg/kg/day Expert practice favors early empiric high-dose CoQ10 despite limited evidence for reversing advanced neonatal neurodegeneration (wahedi2024clinicalfeaturesbiochemistry pages 10-10) Wahedi et al., Neurol Genet (Dec 2024), doi:10.1212/NXG.0000000000200209
Cellular mechanism Patient fibroblasts: reduced cellular CoQ10 in most lines; elevated 6-demethoxyubiquinone (6-DMQ); severe galactose-growth defect with partial rescue by CoQ10 Strong in vitro evidence that COQ4 variants impair CoQ biosynthesis and mitochondrial energy metabolism; exogenous CoQ10 only partially corrects the defect (laugwitz2022humancoq4deficiency pages 21-23) Laugwitz et al., J Med Genet (Oct 2022), doi:10.1136/jmedgenet-2021-107729
Protein-level mechanism COQ4 protein reduced in patient fibroblasts, often with secondary reductions in COQ7/COQ9 Supports the model that COQ4 helps stabilize the CoQ biosynthetic complex (Q-synthome), so deficiency destabilizes the pathway beyond a single enzymatic step (laugwitz2022humancoq4deficiency pages 21-23, laugwitz2022humancoq4deficiency pages 7-8, xie2022primarycoenzymeq10 pages 1-2) Laugwitz et al. 2022; Xie et al., Front Genet (Jan 2022), doi:10.3389/fgene.2021.776807

Table: This table condenses the strongest quantitative evidence for COQ4-related neonatal encephalomyopathy across neonatal case aggregation, the largest human cohort, current treatment practice, and cellular mechanism studies. It is useful for rapidly extracting disease severity, diagnostic yield, treatment response, and mechanistic support from the available literature.

1. Disease information

Definition and scope

The disease is a Mendelian primary mitochondrial CoQ10-biosynthesis disorder. “COQ4-related neonatal encephalomyopathy” is best treated as a severe age-defined presentation within the broader COQ4-deficiency spectrum, rather than as a completely separate molecular disease. The largest systematic cohort separated the spectrum into: (1) prenatal/neonatal brain anomalies and epileptic encephalopathy; (2) an intermediate, stroke-like phenotype; and (3) a moderate, relatively stable phenotype. (laugwitz2022humancoq4deficiency pages 1-3, laugwitz2022humancoq4deficiency pages 10-12)

Identifiers and synonyms

  • MONDO: MONDO:0014562, neonatal encephalomyopathy–cardiomyopathy–respiratory distress syndrome.
  • OMIM/MIM disease: 616227, generally indexed as Coenzyme Q10 deficiency, primary, 7 (COQ10D7).
  • Gene: COQ4, Ensembl ENSG00000167113; approved name coenzyme Q4.
  • Common names: COQ4 deficiency, primary coenzyme Q10 deficiency 7, COQ10D7, COQ4-related mitochondrial disease, COQ4-related encephalomyopathy, and neonatal encephalomyopathy–cardiomyopathy–respiratory distress syndrome. Open Targets associates MONDO:0014562 specifically with COQ4 and cites primary literature including PMIDs 25658047, 26741492, 27604308, 30659264, 31396399, 33215859, 33704555, 36047608, and 38013626. (OpenTargets Search: primary coenzyme Q10 deficiency 7-COQ4)
  • No unique, disease-specific ICD-10, ICD-11, or MeSH code was established in the retrieved evidence; coding ordinarily falls under mitochondrial-metabolism/encephalomyopathy categories.

The evidence is overwhelmingly aggregated disease-level literature, assembled from published case reports, family series, and research cohorts—not population-scale EHR data. The 2022 cohort contained 44 individuals from 36 families, including 16 newly reported patients. (laugwitz2022humancoq4deficiency pages 1-3)

2. Etiology and risk factors

Causal factor

The necessary cause is biallelic germline COQ4 dysfunction, usually homozygous or compound-heterozygous sequence variants, inherited in an autosomal-recessive manner. Reported classes include missense, nonsense, frameshift, splice-altering, and larger deletion alleles. Examples from primary literature include p.Leu82Gln/p.Arg158Gln and homozygous p.Pro64Ser; a chromosome 9q34.13 deletion encompassing COQ4 has also been described. (berardo2020redefininginfantileonsetmultisystem pages 4-6, sondheimer2017novelrecessivemutations pages 4-4)

Genotype–phenotype observations

  • Truncating-plus-missense genotypes were enriched in the severe type-1 phenotype; no individuals with two unequivocal loss-of-function alleles were identified, suggesting complete COQ4 loss may be embryonically nonviable. (laugwitz2022humancoq4deficiency pages 10-12)
  • A proposed exon relationship places variants in exons 1–4 with later, milder, more treatment-responsive disease and variants in exons 5–7 with early severe disease and early death. This remains an observational—not deterministic—rule. (xie2022primarycoenzymeq10 pages 1-2)
  • c.370G>A (p.Gly124Ser; historically reported as p.G124S) is enriched in East Asian/Chinese families and has been associated with intermediate multisystem disease. It should be regarded as a population-enriched pathogenic allele, not proof that southern Chinese ancestry alone causes disease. (berardo2020redefininginfantileonsetmultisystem pages 4-6, xie2022primarycoenzymeq10 pages 1-2)

Other risk, protective, and gene–environment factors

  • Family history and parental consanguinity increase the probability of biallelic inheritance; the recurrence risk is 25% for each pregnancy when both parents are heterozygous carriers.
  • No validated environmental, infectious, toxic, occupational, lifestyle, age-related, or sex-specific cause exists. Sex was not associated with severity in the available analysis. (xie2022primarycoenzymeq10 pages 1-2)
  • No reproducible protective allele, modifier gene, environmental protective factor, or specific gene–environment interaction is established.
  • Claims that epigenetic factors explain intrafamilial variation remain speculative; there is no validated COQ4-specific methylation or chromatin signature. (laugwitz2022humancoq4deficiency pages 10-12)

3. Phenotypes

Major neonatal manifestations

Phenotype Character/course and frequency Suggested HPO term
Neonatal encephalopathy Severe from birth or first days; frequently progressive Neonatal encephalopathy, HP:0012768
Seizures/epileptic encephalopathy Neonatal seizures, recurrent seizures, sometimes status epilepticus Seizure HP:0001250; status epilepticus HP:0002133
Global developmental impairment Profound in survivors; regression may occur Global developmental delay HP:0001263; developmental regression HP:0002376
Hypotonia/weakness Severe axial or generalized hypotonia, decreased movement/cry Muscular hypotonia HP:0001252
Respiratory distress/failure 24/34 in the broader cohort; often ventilatory dependence Respiratory distress HP:0002098; respiratory failure HP:0002878
Feeding difficulty 20/28; may require tube feeding Feeding difficulties HP:0011968
Cardiomyopathy Hypertrophic cardiomyopathy in 15/35; may cause shock Hypertrophic cardiomyopathy HP:0001639; cardiogenic shock HP:0030149
Hyperlactatemia/lactic acidosis 22/31 in the broader cohort and 18/24 neonatal cases; not universal Lactic acidosis HP:0003128; increased serum lactate HP:0011964
Cerebellar abnormality Hypoplasia, atrophy, or cystic degeneration; often prenatal in type 1 Cerebellar hypoplasia HP:0001321; cerebellar atrophy HP:0001272
Cerebral atrophy/delayed myelination Cerebral atrophy in 18; delayed myelination in about half of MRI studies Cerebral atrophy HP:0002059; delayed CNS myelination HP:0002188
Movement disorder Ataxia, dystonia, spasticity, tremor mainly in longer survivors Ataxia HP:0001251; dystonia HP:0001332; spasticity HP:0001257
Visual/oculomotor impairment 17/22 in the broader cohort Visual impairment HP:0000505; abnormal eye movements HP:0012547
Stroke-like episodes Type-2 disease; parieto-occipital lesions, 8–9 reported patients Stroke-like episode HP:0002401

The frequencies come from a clinically heterogeneous, referral-enriched cohort and should not be interpreted as population prevalence. (laugwitz2022humancoq4deficiency pages 8-10, laugwitz2022humancoq4deficiency pages 7-8)

Quality of life

No COQ4-specific EQ-5D, SF-36, PROMIS, or caregiver-burden study was found. Nevertheless, profound developmental disability, refractory epilepsy, ventilatory and feeding support, movement disability, visual impairment, recurrent hospitalization, and early mortality imply extreme patient and caregiver burden. This is a clinical inference rather than a formally measured outcome. (laugwitz2022humancoq4deficiency pages 8-10)

4. Genetic and molecular information

COQ4 encodes a mitochondrial protein required for integrity/stability of the multisubunit CoQ biosynthetic complex (“Q-synthome”); it is not simply a freely acting metabolic enzyme. Reduced COQ4 protein can secondarily lower COQ7 and COQ9, explaining disruption across the pathway. (berardo2020redefininginfantileonsetmultisystem pages 4-6, laugwitz2022humancoq4deficiency pages 21-23, laugwitz2022humancoq4deficiency pages 7-8)

Variants are constitutional/germline, not somatic cancer mutations. Pathogenic interpretation should follow ACMG/AMP criteria using segregation, rarity in population databases, predicted consequence, patient biochemical phenotype, and functional complementation/rescue where available. Exact gnomAD frequencies and ClinVar classifications are variant- and transcript-specific and should be imported directly from current ClinVar/gnomAD records rather than generalized from case literature.

The dominant functional consequence is loss of function or hypomorphic loss of function through reduced protein stability or impaired Q-synthome assembly. Normal COQ4 mRNA with low protein in fibroblasts supports post-transcriptional instability/turnover for some alleles. Missense alleles can leave residual function; complete biallelic loss may be incompatible with survival. (laugwitz2022humancoq4deficiency pages 8-10, laugwitz2022humancoq4deficiency pages 10-12)

No validated modifier gene, disease-specific epigenetic signature, recurrent pathogenic chromosomal rearrangement other than rare deletions encompassing COQ4, or somatic mechanism has been demonstrated.

5. Environmental information

No toxin, radiation exposure, pollutant, occupation, smoking, alcohol use, diet, exercise pattern, or infectious agent has been shown to cause COQ4 deficiency. Environmental stressors such as fasting, fever, hypoxia, or intercurrent infection may plausibly worsen mitochondrial energy failure, but a COQ4-specific interaction has not been quantified. Accordingly, this is a genetic metabolic disease and not an infectious, lifestyle, or environmentally acquired condition.

6. Mechanism and pathophysiology

Causal chain

  1. Biallelic COQ4 variant → reduced/stable-but-dysfunctional COQ4 protein.
  2. Q-synthome destabilization → secondary reduction of other biosynthetic proteins, including COQ7/COQ9.
  3. Defective CoQ synthesis → low CoQ10 and accumulation of 6-DMQ.
  4. Electron-transfer failure between respiratory-chain complexes I/II and III → decreased oxidative phosphorylation and ATP availability.
  5. Compensatory glycolysis → elevated lactate/lactic acidosis.
  6. Loss of CoQ-dependent antioxidant/redox functions may increase oxidative membrane injury and vulnerability to ferroptotic processes; CoQ also participates in pyrimidine metabolism, fatty-acid oxidation, and respiratory-complex stabilization. These broader effects are biologically credible, but their relative contribution in neonatal COQ4 disease has not been quantified. (sondheimer2017novelrecessivemutations pages 4-4, laugwitz2022humancoq4deficiency pages 21-23, xie2022primarycoenzymeq10 pages 1-2)
  7. High-energy tissues fail first: developing neurons and glia, myocardium, skeletal/respiratory muscle → seizures, cerebral/cerebellar injury, hypotonia, cardiomyopathy, respiratory failure, and death.

Direct evidence

Patient fibroblasts showed reduced COQ4 protein, reduced CoQ10 in most lines, 6-DMQ accumulation, and marked growth failure when forced to rely on oxidative metabolism in galactose medium. CoQ10 only partially rescued viability. Muscle studies found low CoQ10 and impaired complex I, II+III, III, and sometimes IV activities. (sondheimer2017novelrecessivemutations pages 4-4, laugwitz2022humancoq4deficiency pages 21-23)

Suggested annotations include:

  • GO biological process: coenzyme Q biosynthetic process; mitochondrial electron transport, NADH to ubiquinone; mitochondrial ATP synthesis coupled electron transport; cellular response to oxidative stress; regulation of ferroptosis.
  • GO cellular component: mitochondrion GO:0005739; mitochondrial inner membrane GO:0005743; respiratory-chain complex/Q-synthome.
  • Cell Ontology: neuron CL:0000540, astrocyte CL:0000127, oligodendrocyte CL:0000128, cardiomyocyte CL:0000746, skeletal muscle cell CL:0000188.
  • CHEBI: coenzyme Q10/ubiquinone-10; ubiquinol-10; lactate; 6-demethoxyubiquinone.

No disease-specific single-cell, spatial-transcriptomic, proteomic, lipidomic, or integrated multi-omic atlas is established. Existing molecular profiling is chiefly targeted immunoblotting, respiratory-chain enzymology, and CoQ/intermediate measurement.

7. Anatomical structures affected

The primary systems are the central nervous system, skeletal/respiratory muscle, and heart. Brain MRI shows bilateral or diffuse cerebral and cerebellar involvement, delayed myelination, thalamic lesions, and—particularly in type 2—parasagittal/parieto-occipital stroke-like lesions. Cerebellar hypoplasia may originate prenatally. (laugwitz2022humancoq4deficiency pages 21-23, laugwitz2022humancoq4deficiency pages 10-12)

Suggested anatomy terms include brain (UBERON:0000955), cerebral cortex (UBERON:0000956), cerebellum (UBERON:0002037), thalamus (UBERON:0001897), heart (UBERON:0000948), myocardium, skeletal muscle tissue (UBERON:0001134), and mitochondrion (GO:0005739). Imaging abnormalities are generally bilateral/diffuse rather than consistently lateralized. Renal disease, prominent in several other CoQ-biosynthesis defects, is not a defining COQ4 feature. (berardo2020redefininginfantileonsetmultisystem pages 4-6)

8. Temporal development

Type-1 disease may begin prenatally with cerebellar hypoplasia, abnormal fetal imaging, prematurity, or impaired fetal well-being. Clinical deterioration is often acute at birth or during the first days, followed by rapidly progressive seizures, respiratory failure, feeding failure, cardiomyopathy, and severe neurodevelopmental injury. In the neonatal review, prenatal abnormalities were more frequent among preterm than term infants (66.7% versus 16.7%, P=0.02). (pan2024thespectrumof pages 1-2, laugwitz2022humancoq4deficiency pages 10-12)

The broader spectrum is lifelong and variable: type 2 can progress through stroke-like episodes and movement disorder into adulthood, whereas type 3 can be comparatively stable. There is no established staging system or spontaneous-remission pattern. The principal therapeutic window is likely before irreversible CNS injury, ideally at molecular diagnosis or even presymptomatically, although proof that neonatal neurologic outcome can be prevented is lacking. (laugwitz2022humancoq4deficiency pages 10-12, wahedi2024clinicalfeaturesbiochemistry pages 10-10)

9. Inheritance, epidemiology, and population

Inheritance is autosomal recessive. Parents of an affected child are typically obligate heterozygotes; each subsequent pregnancy has a 25% affected, 50% carrier, and 25% unaffected/non-carrier probability. Penetrance appears high for genuinely pathogenic biallelic genotypes, but expressivity is broad. Anticipation is not expected. Germline mosaicism has not emerged as a characteristic mechanism, though low residual recurrence risk after apparently de novo findings cannot be universally excluded.

No reliable birth incidence, point prevalence, carrier frequency, or sex ratio exists. A 2024 review stated that approximately 300 patients with all forms of primary CoQ10 deficiency had been diagnosed worldwide; this is not a COQ4-specific prevalence estimate. Half of the 24 neonatal cases in that review were Chinese, probably reflecting p.Gly124Ser enrichment, referral patterns, and publication bias rather than a proven regional incidence. Chinese versus non-Chinese mortality did not differ significantly (75% versus 91.7%, P=0.27). (pan2024thespectrumof pages 1-2)

10. Diagnostics

Recommended approach

  1. Immediate clinical recognition: neonatal seizures/encephalopathy plus hypotonia, respiratory or cardiac failure, feeding difficulty, lactic acidosis, and cerebellar abnormalities should prompt mitochondrial evaluation.
  2. Parallel testing: blood gas, lactate/pyruvate, glucose, ammonia, CK, liver and renal indices, plasma amino acids, urine organic acids, acylcarnitines, ECG/echocardiography, EEG, brain MRI and, where available, MR spectroscopy.
  3. Rapid genomic testing: rapid trio WES/WGS is preferred in critically ill neonates. In the 2024 review, 20/24 cases were diagnosed by WES. A nuclear mitochondrial/CoQ panel including COQ4 is reasonable if rapid and comprehensive, but exome/genome analysis better accommodates phenotypic overlap. (pan2024thespectrumof pages 1-2)
  4. Confirmation: demonstrate biallelic variants with parental segregation. For novel or uncertain variants, measure CoQ10 and respiratory-chain activity in muscle or cultured fibroblasts; COQ4/COQ7/COQ9 immunoblotting and 6-DMQ measurement can provide strong functional support. A normal blood lactate or even normal fibroblast CoQ10 does not exclude disease. (laugwitz2022humancoq4deficiency pages 10-12, xie2022primarycoenzymeq10 pages 7-8)

Muscle biopsy is no longer obligatory when genetics are definitive, but it remains valuable for VUS resolution. CMA can detect a deletion encompassing COQ4 but is insensitive to most pathogenic sequence variants. Karyotype, FISH, mitochondrial-DNA sequencing, and repeat-expansion testing are not first-line tests for isolated suspected COQ4 disease.

Differential diagnosis

Important alternatives include other primary CoQ deficiencies (PDSS1, PDSS2, COQ2, COQ5, COQ6, COQ7, COQ8A/ADCK3, COQ8B/ADCK4, COQ9, HPDL), mtDNA maintenance/translation defects, pyruvate dehydrogenase deficiency, respiratory-chain complex deficiencies, POLG-related disease, neonatal epileptic encephalopathies, congenital disorders of glycosylation, peroxisomal disease, hypoxic–ischemic encephalopathy, infection/sepsis, and structural brain malformations. COQ4 is favored by biallelic COQ4 variants, CoQ/6-DMQ abnormalities, severe cerebellar involvement, cardiomyopathy, and the characteristic parieto-occipital stroke-like pattern in longer survivors. (laugwitz2022humancoq4deficiency pages 1-3, laugwitz2022humancoq4deficiency pages 10-12)

There are no consensus clinical diagnostic criteria, validated newborn biochemical screen, or disease-specific liquid-biopsy/epigenomic test.

11. Outcome and prognosis

The neonatal phenotype has very high mortality. In 24 neonatal-onset cases, mean survival was 60.0 ± 98.0 days; mortality was 9/12 in Chinese and 11/12 in non-Chinese cases. These values are based on published cases and should not be treated as unbiased survival estimates. All four survivors had received CoQ10, but only nine patients were treated, and this uncontrolled observation does not prove efficacy. (pan2024thespectrumof pages 1-2)

Across the broader 44-patient spectrum, only five reached adulthood; cardiorespiratory failure secondary to progressive CNS disease was the principal cause of death. Survivors may have profound intellectual/developmental disability, epilepsy, feeding and mobility dependence, visual impairment, dystonia/spasticity/ataxia, and recurrent stroke-like episodes. No validated 5- or 10-year survival curve, life-expectancy estimate, prognostic calculator, or formal quality-of-life dataset exists. (laugwitz2022humancoq4deficiency pages 8-10)

Poor prognostic indicators include prenatal abnormalities, neonatal onset, profound cerebellar malformation, refractory seizures, cardiorespiratory failure, severe CoQ depletion, and truncating-plus-missense genotypes. These associations remain limited by cohort size.

12. Treatment and current implementation

CoQ10 replacement

Treatment should not await every confirmatory biochemical result when primary CoQ deficiency is strongly suspected. Recent expert practice recommends starting oral CoQ10 promptly and titrating to at least 30 mg/kg/day after molecular confirmation. Historical COQ4 regimens ranged from 15–60 mg/kg/day; the 2024 broader CoQ cohort used doses as high as 70 mg/kg/day. (laugwitz2022humancoq4deficiency pages 7-8, wahedi2024clinicalfeaturesbiochemistry pages 10-10)

However, the COQ4-specific evidence is weak and uncontrolled: among 29 treated patients, 16 had no response and 12 had limited improvement or stabilization, with no clear dose–response relationship. Oral absorption, cellular delivery, and blood–brain-barrier penetration are major limitations. Neurologic injury already present at treatment is generally not reversible. (laugwitz2022humancoq4deficiency pages 7-8)

Direct abstract statement from Laugwitz et al.: “Due to the insufficient clinical response to oral CoQ10 supplementation, alternative treatment strategies are warranted.” The article was published in October 2022; DOI: https://doi.org/10.1136/jmedgenet-2021-107729. (laugwitz2022humancoq4deficiency pages 1-3)

Other interventions

  • Idebenone: one 2024 COQ4 case received 20 mg/kg/day alongside CoQ10 for seizure control, but efficacy cannot be isolated. Idebenone and MitoQ did not improve viability in one COQ4 fibroblast model. (wahedi2024clinicalfeaturesbiochemistry pages 10-10, laugwitz2022humancoq4deficiency pages 8-10)
  • Antiseizure therapy: individualized EEG-guided treatment; avoid valproate when POLG disease has not been excluded or significant hepatic mitochondrial dysfunction exists.
  • Cardiorespiratory care: ventilation, cardiomyopathy/heart-failure therapy, rhythm surveillance, and intensive-care support.
  • Nutrition and rehabilitation: enteral feeding when needed; dietetic, physical, occupational, speech/swallowing, vision, and palliative-care support.
  • Experimental therapy: CoQ precursors/bypass molecules, improved formulations, mitochondrial targeting, and gene replacement/editing are preclinical concepts. No approved COQ4 gene, RNA, or cell therapy exists.

The ClinicalTrials.gov search retrieved no relevant COQ4-specific interventional trial. No pharmacogenomic dosing guideline or validated genotype-guided treatment algorithm exists.

Suggested NCIt intervention concepts: Coenzyme Q10, idebenone, anticonvulsant therapy, mechanical ventilation, enteral nutrition, physical therapy, occupational therapy, speech therapy, and genetic counseling.

13. Prevention

The molecular defect cannot currently be prevented by vaccination, lifestyle modification, or environmental control.

  • Primary genetic prevention: carrier testing for relatives, reproductive counseling, partner testing, prenatal diagnosis by CVS/amniocentesis, and preimplantation genetic testing for a known familial genotype.
  • Secondary prevention: cascade testing and rapid testing of at-risk newborn siblings; early CoQ10 may prevent or slow some tissue injury, although protection against severe neonatal encephalopathy is unproven.
  • Tertiary prevention: aggressive seizure control, aspiration prevention, nutritional support, cardiopulmonary surveillance, prompt treatment of infection, and avoidance of prolonged fasting/dehydration.

COQ4 is not included in routine biochemical newborn screening. Genome-based newborn screening is conceptually relevant but requires evidence that presymptomatic treatment changes neurologic outcome. (wahedi2024clinicalfeaturesbiochemistry pages 10-10)

14. Other species and natural disease

No well-established naturally occurring COQ4 encephalomyopathy in companion animals, livestock, or wildlife was identified, and there is no zoonotic or cross-species transmission. COQ4 is evolutionarily conserved across eukaryotes because CoQ biosynthesis is fundamental to mitochondrial respiration. Relevant research species include Homo sapiens (NCBI Taxon 9606), Mus musculus (10090), Danio rerio (7955), and Saccharomyces cerevisiae (4932). Veterinary breed ontology annotations are therefore not currently applicable.

15. Model organisms and experimental systems

The strongest disease-specific model is the patient-derived dermal fibroblast system. It reproduces reduced COQ4, secondary COQ7/COQ9 reduction, low CoQ10, 6-DMQ accumulation, respiratory dependence, and partial rescue by CoQ10. Its limitation is that fibroblasts do not model developing neurons, glia, myocardium, or blood–brain-barrier delivery. (laugwitz2022humancoq4deficiency pages 21-23)

Yeast provides conserved Q-synthome and complementation systems for studying Coq4 and screening pathway-bypass compounds, but yeast CoQ side-chain chemistry and organismal neurobiology differ from humans. Zebrafish COQ4-loss models have been used to study CNS consequences and therapeutic electron-transfer rescue; their strengths are rapid development and whole-organism imaging, while limitations include species-specific development and drug pharmacokinetics. Robust COQ4 patient-derived iPSC neurons, cerebral/cardiac organoids, and conditional mammalian models remain important unmet needs.

Recent developments and authoritative interpretation

The principal 2023–2024 advances were not a new curative therapy but improved phenotypic definition and treatment implementation. The September 2024 neonatal review quantified the exceptionally poor neonatal survival and showed that WES had become the real-world diagnostic route in 20/24 cases. (pan2024thespectrumof pages 1-2) The December 2024 specialist-center cohort emphasized immediate genome-wide diagnosis and high-dose CoQ10 while cautioning that neonatal neurologic disease can remain fatal despite treatment. Its abstract states: “there are no pathognomonic blood, muscle, or imaging biomarkers of these diseases” and recommends high-dose treatment as soon as possible. DOI: https://doi.org/10.1212/NXG.0000000000200209; published December 2024. (wahedi2024clinicalfeaturesbiochemistry pages 10-10)

The current expert interpretation is therefore balanced: COQ4 deficiency is one of the few inherited mitochondrial disorders with a rational replacement therapy, so delay is inappropriate; nevertheless, oral CoQ10 has poor CNS bioavailability and cannot reliably reverse prenatal or neonatal brain injury. Earlier molecular diagnosis, better delivery across the blood–brain barrier, and validated pathway-bypass or gene-replacement strategies are the highest-priority research needs. (laugwitz2022humancoq4deficiency pages 1-3, wahedi2024clinicalfeaturesbiochemistry pages 10-10, laugwitz2022humancoq4deficiency pages 8-10)

Evidence limitations

All clinical evidence consists of case reports, retrospective cohorts, and literature aggregations. There are no randomized trials, unbiased population registries, validated prevalence estimates, formal QoL studies, standardized outcome measures, or robust natural-history survival analyses. Variant-level database fields—ClinVar status, gnomAD frequency, transcript, and HGVS—must be checked at the time of knowledge-base ingestion because classifications and reference transcripts change. Mechanistic statements about ferroptosis, inflammation, and non-bioenergetic CoQ functions are supported mainly by broader CoQ biology; direct quantification in neonatal COQ4 human brain is absent.

References

  1. (pan2024thespectrumof pages 1-2): Pianpian Pan, Na Zhou, Yi Sun, Zhengrong Chen, Jin Han, and Wei Zhou. The spectrum of clinical manifestations in newborns with the coq4 mutation: case series and literature review. Frontiers in Pediatrics, Sep 2024. URL: https://doi.org/10.3389/fped.2024.1410133, doi:10.3389/fped.2024.1410133. This article has 4 citations.

  2. (laugwitz2022humancoq4deficiency pages 1-3): Lucia Laugwitz, Annette Seibt, Diran Herebian, Susana Peralta, Imke Kienzle, Rebecca Buchert, Ruth Falb, Darja Gauck, Amelie Müller, Mona Grimmel, Stefanie Beck-Woedel, Jan Kern, Karim Daliri, Pegah Katibeh, Katharina Danhauser, Steffen Leiz, Viola Alesi, Fabian Baertling, Gessica Vasco, Robert Steinfeld, Matias Wagner, Ahmet Okay Caglayan, Hakan Gumus, Margit Burmeister, Ertan Mayatepek, Diego Martinelli, Parag Mohan Tamhankar, Vasundhara Tamhankar, Pascal Joset, Katharina Steindl, Anita Rauch, Penelope E Bonnen, Tawfiq Froukh, Samuel Groeschel, Ingeborg Krägeloh-Mann, Tobias B Haack, and Felix Distelmaier. Human coq4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes. Journal of Medical Genetics, 59:878-887, Oct 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107729, doi:10.1136/jmedgenet-2021-107729. This article has 35 citations and is from a domain leading peer-reviewed journal.

  3. (laugwitz2022humancoq4deficiency pages 8-10): Lucia Laugwitz, Annette Seibt, Diran Herebian, Susana Peralta, Imke Kienzle, Rebecca Buchert, Ruth Falb, Darja Gauck, Amelie Müller, Mona Grimmel, Stefanie Beck-Woedel, Jan Kern, Karim Daliri, Pegah Katibeh, Katharina Danhauser, Steffen Leiz, Viola Alesi, Fabian Baertling, Gessica Vasco, Robert Steinfeld, Matias Wagner, Ahmet Okay Caglayan, Hakan Gumus, Margit Burmeister, Ertan Mayatepek, Diego Martinelli, Parag Mohan Tamhankar, Vasundhara Tamhankar, Pascal Joset, Katharina Steindl, Anita Rauch, Penelope E Bonnen, Tawfiq Froukh, Samuel Groeschel, Ingeborg Krägeloh-Mann, Tobias B Haack, and Felix Distelmaier. Human coq4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes. Journal of Medical Genetics, 59:878-887, Oct 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107729, doi:10.1136/jmedgenet-2021-107729. This article has 35 citations and is from a domain leading peer-reviewed journal.

  4. (laugwitz2022humancoq4deficiency pages 7-8): Lucia Laugwitz, Annette Seibt, Diran Herebian, Susana Peralta, Imke Kienzle, Rebecca Buchert, Ruth Falb, Darja Gauck, Amelie Müller, Mona Grimmel, Stefanie Beck-Woedel, Jan Kern, Karim Daliri, Pegah Katibeh, Katharina Danhauser, Steffen Leiz, Viola Alesi, Fabian Baertling, Gessica Vasco, Robert Steinfeld, Matias Wagner, Ahmet Okay Caglayan, Hakan Gumus, Margit Burmeister, Ertan Mayatepek, Diego Martinelli, Parag Mohan Tamhankar, Vasundhara Tamhankar, Pascal Joset, Katharina Steindl, Anita Rauch, Penelope E Bonnen, Tawfiq Froukh, Samuel Groeschel, Ingeborg Krägeloh-Mann, Tobias B Haack, and Felix Distelmaier. Human coq4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes. Journal of Medical Genetics, 59:878-887, Oct 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107729, doi:10.1136/jmedgenet-2021-107729. This article has 35 citations and is from a domain leading peer-reviewed journal.

  5. (laugwitz2022humancoq4deficiency pages 10-12): Lucia Laugwitz, Annette Seibt, Diran Herebian, Susana Peralta, Imke Kienzle, Rebecca Buchert, Ruth Falb, Darja Gauck, Amelie Müller, Mona Grimmel, Stefanie Beck-Woedel, Jan Kern, Karim Daliri, Pegah Katibeh, Katharina Danhauser, Steffen Leiz, Viola Alesi, Fabian Baertling, Gessica Vasco, Robert Steinfeld, Matias Wagner, Ahmet Okay Caglayan, Hakan Gumus, Margit Burmeister, Ertan Mayatepek, Diego Martinelli, Parag Mohan Tamhankar, Vasundhara Tamhankar, Pascal Joset, Katharina Steindl, Anita Rauch, Penelope E Bonnen, Tawfiq Froukh, Samuel Groeschel, Ingeborg Krägeloh-Mann, Tobias B Haack, and Felix Distelmaier. Human coq4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes. Journal of Medical Genetics, 59:878-887, Oct 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107729, doi:10.1136/jmedgenet-2021-107729. This article has 35 citations and is from a domain leading peer-reviewed journal.

  6. (wahedi2024clinicalfeaturesbiochemistry pages 10-10): Azizia Wahedi, Sniya Sudhakar, Amanda Lam, Jose Ignacio Rodriguez Ciancio, Philippa Mills, Paul Gissen, Alice Gardham, Jogesh Kapadia, Jane Hassell, Simon Heales, and Shamima Rahman. Clinical features, biochemistry, imaging, and treatment response in a single-center cohort with coenzyme q 10 biosynthesis disorders. Neurology Genetics, Dec 2024. URL: https://doi.org/10.1212/nxg.0000000000200209, doi:10.1212/nxg.0000000000200209. This article has 6 citations.

  7. (laugwitz2022humancoq4deficiency pages 21-23): Lucia Laugwitz, Annette Seibt, Diran Herebian, Susana Peralta, Imke Kienzle, Rebecca Buchert, Ruth Falb, Darja Gauck, Amelie Müller, Mona Grimmel, Stefanie Beck-Woedel, Jan Kern, Karim Daliri, Pegah Katibeh, Katharina Danhauser, Steffen Leiz, Viola Alesi, Fabian Baertling, Gessica Vasco, Robert Steinfeld, Matias Wagner, Ahmet Okay Caglayan, Hakan Gumus, Margit Burmeister, Ertan Mayatepek, Diego Martinelli, Parag Mohan Tamhankar, Vasundhara Tamhankar, Pascal Joset, Katharina Steindl, Anita Rauch, Penelope E Bonnen, Tawfiq Froukh, Samuel Groeschel, Ingeborg Krägeloh-Mann, Tobias B Haack, and Felix Distelmaier. Human coq4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes. Journal of Medical Genetics, 59:878-887, Oct 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107729, doi:10.1136/jmedgenet-2021-107729. This article has 35 citations and is from a domain leading peer-reviewed journal.

  8. (xie2022primarycoenzymeq10 pages 1-2): Jieqiong Xie, Jiayang Jiang, and Qiwei Guo. Primary coenzyme q10 deficiency-7 and pathogenic coq4 variants: clinical presentation, biochemical analyses, and treatment. Frontiers in Genetics, Jan 2022. URL: https://doi.org/10.3389/fgene.2021.776807, doi:10.3389/fgene.2021.776807. This article has 17 citations and is from a peer-reviewed journal.

  9. (OpenTargets Search: primary coenzyme Q10 deficiency 7-COQ4): Open Targets Query (primary coenzyme Q10 deficiency 7-COQ4, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  10. (berardo2020redefininginfantileonsetmultisystem pages 4-6): Andres Berardo and Catarina M. Quinzii. Redefining infantile-onset multisystem phenotypes of coenzyme q10-deficiency in the next-generation sequencing era. Journal of translational genetics and genomics, 4:22-35, Apr 2020. URL: https://doi.org/10.20517/jtgg.2020.02, doi:10.20517/jtgg.2020.02. This article has 17 citations.

  11. (sondheimer2017novelrecessivemutations pages 4-4): Neal Sondheimer, Stacy Hewson, Jessie M. Cameron, Gino R. Somers, Jane Dunning Broadbent, Marcello Ziosi, Catarina Maria Quinzii, and Ali B. Naini. Novel recessive mutations in coq4 cause severe infantile cardiomyopathy and encephalopathy associated with coq 10 deficiency. Sep 2017. URL: https://doi.org/10.1016/j.ymgmr.2017.05.001, doi:10.1016/j.ymgmr.2017.05.001. This article has 43 citations.

  12. (xie2022primarycoenzymeq10 pages 7-8): Jieqiong Xie, Jiayang Jiang, and Qiwei Guo. Primary coenzyme q10 deficiency-7 and pathogenic coq4 variants: clinical presentation, biochemical analyses, and treatment. Frontiers in Genetics, Jan 2022. URL: https://doi.org/10.3389/fgene.2021.776807, doi:10.3389/fgene.2021.776807. This article has 17 citations and is from a peer-reviewed journal.

Artifacts